


# **5th World Congress on ADHD**

From Child to Adult Disorder



28 – 31 May 2015

Scottish Exhibition and Conference Centre (SECC)

**Glasgow | Scotland** 



www.adhd-congress.org

# **TABLE OF CONTENTS**

	Page
Welcome Address	3
Organization	4
Committees	5
World Federation of ADHD	6
Overview of Meeting Rooms	7
Format Descriptions	9
Opening Ceremony	10
Programme Overview	11
Scientific Programme Thursday, 28 May 2015 Friday, 29 May 2015 Saturday, 30 May 2015 Sunday, 31 May 2015	18 31
Educational Goals	45
General Information Congress Venue Congress Registration Counter Registration Fees Certificate of Attendance Name Badges Loss of Name Badges Congress Language EACCME – Continuing Medical Education Publications for Proceedings Internet Digital Service Area Congress Information System W-LAN/Wi-Fi Congress APP Technical Exhibition Poster Exhibition Poster Exhibition Awards Speakers Centre Restaurants Coffee Breaks and Lunch Cloakroom Bank Currency Electricity Loct and Found	48 48 49 49 49 49 49 50 50 50 51 51 51 51
Lost and Found Mobile Phones Programme Changes	51

	Page
Climate Press	51
Insurance Registration Conditions	
Official Italian Agency	
How to get from the Airport	
to the Congess Venue	52
Public Transportation	
Car Park	52
Taxis	52
Acknowledgements	53
Satellite Symposia	53
List of Exhibitors and Map	54
List of Chairpersons and Presenters	55

## **CONGRESS APP**

Get the 5<sup>th</sup> World Congress on ADHD 2015 APP for your smart phone now and experience the congress at your fingertips! Quickly find your way through the most up-to-date congress schedule. Stop carrying around piles of paper. Just take the congress with you, wherever and whenever you want! The APP is completely free and provides iPhone/iPad, Android Smartphone users at the 5<sup>th</sup> World Congress on ADHD 2015 in Glasgow.





ADHD

2015

The ADHD 2015 APP is powered by GLOBIT's acclaimed CONGRESS MOBILE® software.

Further information is given at www.adhd-congress.org/app/mobile



## WELCOME ADDRESS



Luis A. Rohde


Dear Colleagues and Friends,

It is now the fifth time that the World Congress on ADHD takes place, and we are happy to remember our tradition of bringing together healthcare specialists from all around the world, dedicated to this challenging and extremely relevant mental disorder.

More than 2,000 participants from 86 countries attended our last meeting in Milan. We got enthusiastic comments confirming that this was a key meeting for acquiring the most recent and authoritative information on all aspects of ADHD.

We welcome you to Glasgow and we are very proud to have the chance to organize once again a top level event, adressing key issues in the field of ADHD. A warm and friendly atmosphere will encourage the participants to share their experience and knowledge with each other.

Our key issues are: New advances in ADHD diagnosis, treatment and neurobiology, as well as controversial issues in the field.



Furthermore, three new formats will be introduced in the upcoming Congress: In our Late breaking news, speakers present very new research results in the field of preclinical and clinical research on ADHD. In the Grand round and Historical case, clinical cases will be discussed by some of the most reputed ADHD experts.

Glasgow is the ideal place for this meeting. The beautiful city is located at the River Clyde, close to the Atlantic Ocean. With approximately 600,000 citizens and roughly 2 million in the greater region, the city invites you to discover its medevial architecture during pleasant strolls. In the city traditional businesses go hand in hand with modern life. If you are interested in art, the city centre is the home to the Gallery of Modern Art (GoMA) and the McLellan Galleries, built in 1855-56, now considered the largest quality, climate-controlled, temporary exhibition gallery in Scotland.

Take the chance to aquire the latest knowledge in the field of ADHD and network with old and new friends.

Thank you very much for your participation!

Yours sincerely,

Prof. Luis A. Rohde Congress President President World Federation

of ADHD

Prof. Manfred Gerlach Chairman Scientific Programme Committee





Manfred Gerlach

## **ORGANIZATION**

## **CONGRESS PRESIDENT**

Prof. Luis A. Rohde Federal University of Rio Grande do Sul 90040-060 Porto Alegre, Brazil Email: adhd2015@cpo-hanser.de

## CHAIR SCIENTIFIC COMMITTEE

Prof. Manfred Gerlach University of Würzburg 97080 Würzburg, Germany Email: adhd2015@cpo-hanser.de

## **CONGRESS VENUE**

Scottish Exhibition and Conference Centre SECC Exhibition Way
Glasgow G3 8YW, United Kingdom

#### **ORGANIZER**

## World Federation of ADHD

Global Head Office Zum Ehrenhain 34 22885 Barsbüttel, Germany Phone:+49-40-670 88 20

Fax: +49-40-670 32 83 Email: adhd@cpo-hanser.de

## CONGRESS AND EXHIBITION OFFICE

# CPO HANSER®

## **Hamburg Office**

Hanser & Co GmbH Zum Ehrenhain 34 22885 Barsbüttel, Germany Phone:+49-40-670 88 20

Fax: +49-40-670 32 83 Email: adhd2015@cpo-hanser.de



## **COMMITTEES**

## SCIENTIFIC PROGRAMME COMMITTEE

## Chair: M. Gerlach, Germany

P. Asherson, United Kingdom

T. Banaschewski, Germany

M. Bellgrove, Australia

j. Biederman, USA

J. Buitelaar, The Netherlands

F. X. Castellanos, USA

D. Coghill, United Kingdom

M. Döpfner, Germany

S. Durston, The Netherlands

S. Faraone, USA

B. Franke, The Netherlands

C. Freitag, Germany

L. Greenhill, USA

J. Halperin, USA

S. Kasper, Austria

R. Klein, USA

S. Kooij, The Netherlands

C. J. Kratochvil, USA

K. Lange, Germany

J. O. Larsson, Sweden

K.-P. Lesch, Germany

I. Manor, Israel

A. Miranda, Spain

M. Muenke, USA

J. Newcorn, USA

A. Philipsen, Germany

J. A. Ramos-Quiroga, Spain

F. W. Reimherr, USA

P. Riederer, Germany

M. Rösler, Germany

L. A. Rohde, Brazil

A. Rothenberger, Germany

K. Rubia, United Kingdom

R. Schachar, Canada

D. Silva, Australia

C. Soutullo, Spain

R.-D. Stieglitz, Switzerland

Y. Taneli, Turkey

R. Tannock, Canada

J. Thome, Germany

T. Torgersen, Norway

O. Tucha, The Netherlands

G. van de Glind, The Netherlands

A. Vetro, Hungary

S. Walitza, Switzerland

A. Warnke, Germany

M. Weiss, Canada

T. E. Wilens, USA

E. Willcut, USA

E. Wolters, The Netherlands

Y. Zheng, China

#### LOCAL ORGANIZING COMMITTEE

P. Asherson, London, United Kingdom

D. Coghill, Dundee, United Kingdom

## WORLD FEDERATION OF ADHD

#### WORLD FEDERATION OF ADHD

In August 2008, the World Federation of ADHD (Attention Deficit Hyperactivity Disorder) and allied disorders was founded in Zurich, Switzerland. Prof. Dr. Andreas Warnke, Director of the Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy at the University of Würzburg, Germany was officially nominated the first president of this non-profit organisation.

ADHD is a highly heritable childhood-onset psychiatric condition which is characterized by age-inappropriate levels of the core symptoms inattention, hyperactivity and impulsivity. The disorder affects about 5% of children world-wide. Recent scientific studies in ADHD reveal biological underpinnings such as multiple genetic factors, ADHD-related differences in brain structure and function as well as changes in neurotransmitter components within the basal ganglia thalamocortical neurocircuitries. The purpose of the World Federation of ADHD and allied disorders is to support and promote clinical studies, scientific projects and training programmes in the field of ADHD and related disorders worldwide, as well as to enhance the exchange of information between scientists, physicians, health experts, ADHD lay organisations, and the public. The website of the federation www.adhd-federation.org presents on a monthly updated basis the latest abstracts in the field of ADHD and is networking with related associations and institutions.

**World Federation of ADHD, Global Head Office** CPO HANSER SERVICE Zum Ehrenhain 34

22885 Barsbüttel, Germany

Phone: +49 – 40 – 670 88 20 Fax: +49 – 40 – 670 32 83 Email: adhd@cpo-hanser.de

# General Assembly 28 May 2015 | 13:30-14:30 | Hall Boisdale 2


## **BECOME A MEMBER NOW!**

#### Your benefits

- Substantially reduced registration fees for World Congress of ADHD Congresses in Glasgow 2015 and Vancouver 2017
- Access to the latest abstract reviews
- A selection of the latest and most important abstract issues in seven different categories will be prepared for all members. One of the most efficient ways to kept updated!
- Access to the Springer journal link of ADHD
- Benefit from a free access to the online journal of the ADHD Attention Deficit and Hyperactivity Disorders and review latest results
- Networking with colleagues worldwide
- ▶ Reasonable annual membership fee EUR 50

▶ ► Visit us at www.adhd-federation.org

# **OVERVIEW OF MEETING ROOMS**





www.adhd-federation.org

# World Federation of ADHD Attention Deficit Hyperactivity Disorder



www.adhd-congress.org

## **BENEFITS TO BECOME AN ADHD MEMBER**

- Exchanging information on developments
- Advance the clinical and basic research
- Scientific, scholarly and educational training
- Collaboration with other related professional and lay organisations

Global Head Office and Congress and Exhibition Office



CPO HANSER SERVICE Zum Ehrenhain 34 22885 Barsbüttel, Germany

Phone: +49 - 40 - 670 882 0 Fax: +49 - 40 - 670 32 83 Email: adhd@cpo-hanser.de

## FORMAT DESCRIPTIONS

#### PLENARY SESSIONS (PL)

Duration: 90/120 min.

Plenary sessions will feature authoritative scientific updates on a comprehensive range of topics. Each daily session is composed of three to four 30-minute lectures presented by international leaders in the field of ADHD. After the talk there will be no discussion.

## HOT TOPIC SYMPOSIA (HT)

Duration: 90 min.

Hot topic symposia will feature comprehensive reviews of the most recent research results as well as practical issues in the field of ADHD. Each 90-minute symposium, presented by internationally recognized clinicians and neuroscientists, contains a theme of topical interest and is composed of three or four lectures, with a maximum of 20 minutes. After the talks there will be a short discussion.

## RESEARCH CONSORTIA BRIEFING (RC)

Duration: 90 minutes

The research consortia briefings will last 90 minutes. Experts in the field of neurology and psychiatry will present new designs and findings and will discuss these issues with participants.

#### LATE BREAKING NEWS (LB)

**Duration 90 minutes** 

Within this session the latest abstract reviews issued shortly before the congress will be presented and discussed by the reviewer of the World Federation of ADHD and the auditorium.

## **GRAND ROUND**

Duration: 90 min.

Led by a moderator, three ADHD experts discuss a clinical case within the field of ADHD.

### **EDUCATIONAL SEMINARS (ES)**

Duration: 60 min.

Educational seminars are designed to be informal and interactive and will feature an update on clinical relevant topics. Each 60-minute seminar is composed of one, respectively two lectures and is followed by a discussion. To

facilitate coordination, attendance is limited. Therefore it is recommendable to book the ticket together with the congress registration online or to check ticket availability on site at the registration counter. Tickets will be handled on a 'first-come, first-served' basis.

Registration fee per session: EUR 30.

Only valid in combination with the congress registration fee.

#### MEET-THE-EXPERT SESSIONS (ME)

Duration: 60 min.

Meet-the-expert sessions have been specifically designed to provide an informal atmosphere where doctors and scientists can interact with internationally renowned experts in the field of ADHD. The sessions are especially suitable for the exchange of knowledge and aim at first-hand learning about the latest clinical (practical) and scientific advancements. Meet-the-expert sessions are open to all participants but tickets are handled strictly on a 'first-come, first-served' basis.

Registration fee per session: EUR 30.

Only valid in combination with the congress registration fee.

#### **GUIDED POSTER TOURS (P)**

Duration: 90 min.

All accepted posters will be presented during guided poster tours. The posters will be displayed in the poster exhibition. Whenever possible, the lead or senior authors must be present during the presentation. The presenting author has to be registered.

#### YOUNG SCIENTISTS' SESSIONS (YS)

Duration: 90 min.

Selected by the Scientific Programme Committee eight young scientists have the possibility to present their findings. Chaired by recognized experts in the featured topic, these interdisciplinary sessions are composed of 20-minute lectures, followed by short discussions.

## INDUSTRY SPONSORED SYMPOSIA

Duration: 60-75 min.

Satellite symposia will be organized by pharmaceutical companies and are open to all congress delegates. These sessions are scheduled during the congress and will not interfere with the scientific programme.



# **OPENING CEREMONY**

Thursday, 28 May 2015



## **OPENING CEREMONY**

19:00 | Clyde auditorium


## **Welcome to Glasgow**

- Welcome Address by the Congress President Prof. Luis A. Rohde, Brazil and by the City Council of Glasgow
- Welcome Address by President of ADHD Europe Andrea Bilbow OBE, United Kingdom
- Opening lecture
   Prof. Peter McGuffin, United Kingdom
   What psychiatric genetics has taught us about the nature of psychiatric disorders and what there is left to learn
- Award ceremony and honouring of Paul Wendler, USA for his life time work with the medal of the World Federation of ADHD
- Traditional Glasgow bagpipe performance

At the end of the Opening ceremony all participants are invited to join the Networking Reception in the exhibition area hall 2.

The Networking Reception is kindly supported by Glasgow City Council

Thursday, 28 May 2015



## **Abbreviations**

ES	Educational Seminar
ME	Meet-the-Expert Session
PL	Plenary Session

HT	Hot Topic Symposium		
RC	Research Consortia Session		
LB	Late Breaking News		

YS	Young Scientist Session
SA	Industry Sponsored Session
P	Guided Poster Tour



11:00    PL-1   New advances in ADHD diagnosis treatment and a clinical report	09:00	New advances in ADHD diag-						in the Foyer: <b>Registration</b> 07:30 – 18:00
Table 11:00 - Coffee Break  Coffee Break  Coffee Break  Coffee Break  Coffee Break  Coffee Break  Lunch Break  SA-01 Industry sponsored session  Lunch Break  Lunch Break  HT-6 Potential adverse health outcomes in the treatment of ADHD  ADHD in the classroom disorders (ASD) and ADHD  RC-3 Eunethydis consortium: The Europea guideline gro	10:00	_						Technical Exhibition 09:00-17:30
13:00 -  Lunch Break  SA-01 Industry sponsored session  Lunch Break  Lunch Break  Lunch Break  HT-6 Potential adverse health outcomes in the treatment of ADHD  ADHD in the classroom  HT-8 ADHD in the classroom  ADHD in the classroom  Freatment options of adult ADHD  RC-3 Eunethydis consortium: The Europea guideline gro								Poster Exhibition 09:00-17:30
12:00 - Lunch Break  SA-01 Industry sponsored session  Lunch Break  Lunch Break  HT-6 Potential adverse health outcomes in the treatment of ADHD  ADHD in the classroom options of adult options of adult autism spectrum disorders (ASD) and ADHD  HT-8 ADHD in the classroom options of adult ADHD  RC-3 Eunethydis consortium: The Europea guideline ground in the classroom options of adult adverse guideline ground in the classroom options of adult adver	11:00			Coffee Break				
Lunch Break  HT-6 Potential adverse health outcomes in the treatment of ADHD  HT-7 Neurocognitive findings in autism spectrum disorders (ASD) and ADHD  HT-8 ADHD in the classroom  Treatment options of adult ADHD  RC-3 Eunethydis consortium: The Europea guideline gro		A case presentation of a young adult requesting ADHD diagnosis, treatment and a						
Potential adverse health outcomes in the treatment of ADHD  Neurocognitive findings in autism spectrum disorders (ASD) and ADHD  ADHD in the classroom  Treatment options of adult ADHD  Eunethydis consortium: The Europea guideline ground and ADHD		Lunch Break	Industry sponsored		Lunch E	Break		
10.00	15:00		Potential adverse health outcomes in the treatment	Neurocogni- tive findings in autism spectrum disorders (ASD)	ADHD in the	Treatment options of adult	Eunethydis	
Coffee Break 16:00 – 17:30: Guided Poster Tours P-1 – P-16	16:00		OI ADIID					
17:00 - ES-3 New assessment strategies of ADHD in adults  ES-4 To treat or not to treat—controversies and difficulties related to treatment  ES-2 Ambulatory assessment to study ADHD patients in their natural  ES-1 Organisation and carrying out of parent training in ADHD genetics and how they might inform  ME-1 Diagrams in ADHD genetics and how they might inform  ME-2 ME-2 ADHD over the lifeton					ours P-1 – P-16			Guided Poster Tours P-1 – P-16

Room	Clyde	Forth	Lomund	Alsh 1/2	Carron 1/2	Dochart 1/	Boisdale 1/2	Foyer/Hall 2
08:30 - 09:00 -	PL-2 New advances in ADHD neuro-							in the Foyer: Registration 08:00-18:00
_	biology							Technical Exhibition 09:00-17:30
10:00 -								Poster Exhibition 09:00-17:30
11:00 -				Coffee Break				
12:00 -	PL-3 Role play clinical interview: An ADHD evalu- ation of young John F. Kennedy							
13:00 -		SA-02 Industry sponsored session		Lunch Break				
14:00 –								
15:00 <b>–</b>		HT-10 Towards an evidence-based taxonomy of non-pharmaco- logic treatments for ADHD	HT-11 Recent data from adult ADHD follow-up studies	HT-12 Early life factors as origin of ADHD	HT-13 Neurobiological mechanisms underlying drug treatment in ADHD	HT-14 Unstable wake- fulness regula- tion: A common pathogenetic factor in ADHD and manier	HT-15 Dopaminer- gic motor behavioural and behavioural mo- tor disorders	
16:00 -				C (( D )				Guided
_	Coffee Break  16:00 – 17:30: Guided Poster Tours P-17 – P-32				Poster Tours P-17 – P-32			
17:00 -		<b>ES-7</b> Oppositional defiant disorder and ADHD	ES-8 Optimizing medication management of adult ADHD	ES-6 Non-pharmaco- logic treatment of ADHD in children and adolescents	Paying attention in meta-analyses: Learning to read them through recent	ME-7 New ways of understanding ADHD neuro- psychology and how they	Boisdale 1: ME-5 Neurobi- ology of ADHD Boisdale 2: ME-6 Treat- ment of adult	16:00 – 17:30
18:00 –								



Saturday, 31 May 2015

Room	Clyde	Forth	Lomund	Alsh 1/2	Carron 1/2	Dochart 1/	Boisdale 1/2	Foyer/Hall 2
08:30 – 09:00 –	PL-4 Controversies in ADHD							in the Foyer: Registration 08:00-13:30  Technical Exhibition 09:00-13:00
10:00 -								Poster Exhibition 09:00-13:00
11:00 -				Coffee Break				
12:00 –	PL-3 New advances in the treatment of ADHD							
_								
13:00 – 13:30	Closing Ceremony							

## **EACCME – CONTINUING MEDICAL EDUCATION**

The 5<sup>th</sup> World Congress on ADHD is accredited by the European Accreditation Council for Continuing Education in Brussels (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS), www.uems.net.

The 5<sup>th</sup> World Congress on ADHD is designated for maximum 18 CME credit points of European external CME credits. Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Please hand in the evaluation form enclosed in the congress bag to receive a printed copy of the accreditation certificate.

Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME credit to AMA credit can be found at www.ama-assn.org/go/internationalcme.

Live educational activities, occurring outside of Canada, recognized by the UEMS-EACCME for ECMEC credits are deemed to be Accredited Group. Learning Activities (Section 1) as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada.

Thursday, 28 May 2015

**General Assembly** 

13:30 – 14:30 Boisdale 2

General Assembly (for members only)

HT-1	<b>Hot Topic Symposium</b>

15:00 – 16:30 Lomund Auditorium

ADHD and comorbidity

Chairs: F. Reimherr, USA

S. Kooij, The Netherlands

HT-1-001 The relevance of comorbidity in adult

**ADHD** 

F. Reimherr, USA

HT-1-002 Obesity in ADHD

S. Cortese, Italy

HT-1-003 Sleep disorders and ADHD

S. Kooij, The Netherlands

HT-2 Hot Topic Symposium

15:00-16:30 Carron 1/2

Treatment and course of ADHD in offenders

Chairs: M. Rösler, Germany

S. Young, United Kingdom

HT-2-001 Ten-year follow-up in juvenile and young

adult offenders

F. Philipp-Wiegmann, Germany

HT-2-002 Impact of ADHD on the legal prognosis

of young offenders: A ten-year follow-up

W. Retz, Germany

HT-2-003 Psychosocial treatment of offenders with

ADHD

S. Young, United Kingdom

HT-2-004 Pharmacological treatment of offenders

with ADHD

Y. Ginsberg, Sweden

HT-3 Hot Topic Symposium

15:00-16:30 Dochart 1/2

Cross-cultural issues in ADHD

Chairs: K. W. Lange, Germany

D. Silva, Australia

HT-3-001 ADHD across cultures: Bona fide mental

disorder versus social construction

K. W. Lange, Germany

HT-3-002 Clinical impact of ADHD in South America

L. Viola, Uruguay

HT-3-003 Medical and social aspects of ADHD in

Δsia

Y. Zheng, People's Republic of China

HT-3-004 Life course of ADHD for Aboriginals com-

pared to non-Aboriginal children

D. Silva, Australia

YS-1 Young Scientist Session

15:00 – 16:30 Boisdale 2

Young Scientists'Session I

Chairs: F. X. Catellanos, USA

K. Rubia, United Kingdom

YS-1-001 Cortico-striatal network dysfunction in

ADHD

M. Oldehinkel, The Netherlands

YS-1-002 Double-dissociation between the mecha-

nisms leading to impulsivity and inattention in Attention-Deficit/Hyperactivity

Disorder: A resting state functional con-

nectivity study

V. Parlatini, United Kingdom

YS-1-003 Associations between serotonin trans-

porter gene (SLC6A4) methylation and clinical characteristics and cortical thick-

ness in children with ADHD

S. Park, Republic of Korea

YS-1-004 (Grey) matter of attention: Cortical mor-

phometry in Attention Deficit/Hyper-

**activity Disorder** T. J. Silk, Australia



Thursday, 28 May 2015

RC-1	Research Consortia Session	HT-5	Hot Topic Symposium
15:00-16:30	Alsh 1/2	17:00-18:30	Dochart 1/2
	ubstance abuse: Causes and options for nd prevention G. van de Glind, The Netherlands	The current s Chairs:	A. Fallgatter, Germany K. Rubia, United Kingdom
RC-1-001	J. A. Ramos-Quiroga, Spain  ADHD, substance abuse disorders and genetics  J. A. Ramos-Quiroga, Spain	HT-5-001	fMRI neurofeedback in adolescents with ADHD K. Rubia, United Kingdom
RC-1-002	Inhibition deficits and substance abuse disorders development I. Ivanov, USA	HT-5-002 HT-5-003	A randomized controlled multicentre
RC-1-003	Cognitive behavioral therapy for patients with ADHD and substance use disorders K. van Emmerik-van Oortmerssen, The Netherlands E. Vedel, W. van den Brink, R. Schoevers	HT-5-004	study on the efficacy of slow cortical po- tential neurofeedback in ADHD D. Brandeis, Germany Neurofeedback in ADHD: Meta-analysis, current state and future perspectives
RC-1-004	Current practice in Belgium on ADHD and substance abuse disorders F. Matthys, Belgium	YS-2	M. Arns, The Netherlands  Young Scientist Session

16:30 – 17:00	Break	Young Scier Chairs:	ntists´Session II L. A. Rohde, Brazil	
HT-4	Hot Topic Symposium		S. Walitza, Switzerland	
17:00 – 18:30 Real outcom Chairs:	Lomund Auditorium es of ADHD O. Tucha, The Netherlands	YS-2-001	Has the prevalence of ADHD increased during the last decade? M. Rydell, Sweden	
HT-4-001	N.N.  Neuropsychology of adult ADHD – searching for the impact on real life O. Tucha, The Netherlands	YS-2-002	Birth weight predicts adolescent brain volume in participants with ADHD, unaf- fected siblings and control participants C. Greven, The Netherlands	
HT-4-002	School underachievement A. B. M. Fuermaier, The Netherlands	YS-2-003	Antisocial outcomes and psychiatric, social and familial risk factors – a nationwide controlled Danish registry study	
HT-4-003	Mortality in children, adolescents and adults with ADHD S. Dalsgaard, Denmark		C. M. Jensen, Denmark	

Risky sexual behaviour and pregnancy in

adolescence with ADHD

D. E. Sarver, USA

Break

17:00-18:30

**Boisdale 2** 

HT-4-004

16:30 - 17:00

Thursday, 28 May 2015

YS-2-004 Functional glucocorticoid receptor gene

variants, childhood ADHD and comor-

bidities

A. Schote-Frese, Germany

LB-1 Late Breaking News

17:00 – 18:30 Carron 1/2

Chairs: G. Salum, Brazil

J. Thome, Germany

RC-2 Research Consortia Session

17:00-18:30 Alsh 1/2

**IMpACT** consortium

Chairs: B. Franke, The Netherlands

J. Haavik, Norway

RC-2-001 Consortium science: How can international

collaboration move forward our research on psychiatric disorders and ADHD in par-

ticular?

B. Franke, The Netherlands

RC-2-002 Does relative age at the start of school

influence the prevalence of ADHD diagnosis, and what are the long-term implica-

tions?

J. Kuntsi, United Kingdom

RC-2-003 A large meta-analysis of neuroimaging

data implicates delays in maturation but also increased neurodegeneration in

ADHD

M. Hoogman, The Netherlands

RC-2-004 Rare genetic variants in (adult) ADHD

J. Haavik, Norway

**Opening Lecture** 

19:00-20:30

**Clyde Auditorium** 

**Opening Lecture & Ceremony** 

Followed by a Networking Reception supported by Glasgow Civic Council.

Full schedule of the Opening Ceremony ist provided on page 10.



Friday, 29 May 2015

PL-1	Plenary Session	НТ-6	Hot Topic Symposium
08:30-10:30	Clyde Auditoriun	n 14:30–16:00	Lomund Auditorium
New advance Chairs:	ces in ADHD diagnosis S. Walitza, Switzerland A. Warnke, Germany	Potential ad of ADHD Chairs:	R. G. Klein, USA
PL-1-001	Approaches to improving ADHD subtypin using Research Domain Criteria (RDoC and clinical intuition J. T. Nigg, USA		T. Renner, Germany  Does childhood ADHD predict risk-taking and medical illness in adulthood?  R. G. Klein, USA
PL-1-002	Should emotional dysregulation be a confeature in the ADHD diagnosis? P. Asherson, United Kingdom		Cardiovascular safety of psychostimulants in children with ADHD: Findings from a population-based cohort study S. Dalsgaard, Denmark
PL-1-003	How new ways of analysing neuroimagin data can improve differential diagnosis i ADHD?  D. Fair, USA	-	Psychostimulant treatment and blood pressure: Results from a naturalistic study T. Renner, Germany
PL-1-004	J. Nigg, O. Miranda-Dominguez  Current status and future perspectives of neurobiological measures/tests in ADH diagnosis  T. Banaschewski, Germany		The association between medication for ADHD and cancer HC. Steinhausen, Denmark
	i. Daliaschewski, Germany	HT-7	Hot Topic Symposium
10:30 – 11:0	0 Brea	k 14:30-16:00	Alsh 1/2
GR-1	Grand Round		tive findings in autism spectrum SD) and ADHD-overlap or specific
11:00 – 12:30 A case prese	Clyde Auditorium chation of a young adult requesting	· ·	J. Buitelaar, The Netherlands G. Kohls, Germany
	nosis, treatment and a clinical report for ccommodation in an MBA entrance test L. A. Rohde, Brazil M. Weiss, Canada, J. Biederman,	HT-7-001	Disentangling reward dysfunction in ADHD versus ASD G. Kohls, Germany
	USA, E. Taylor, UK	HT-7-002	Attention processing in inattentive and combined ADHD and ASD
12:30 – 14:3	Lunch Brea	K	J. Volkert, Germany

please see page 53.

**Industry Sponsored Symposium** 

**Lomond Auditorium** 

SA-01

12:45 - 14:00

Friday, 29 May 2015

HT-7-003 The need for a lifespan approach in HT-9-003 Novel treatment strategies studying common mechanisms underly-C. B. Surman, USA ing neurodevelopmental disorders HT-9-004 N. Lambregts-Rommelse, The Netherlands

HT-7-004 Shared and unique underpinnings of ASD and ADHD. Pre-/perinatal antecedents and cognitive deficits in the context of

familial risk

A. Oerlemans, The Netherlands

HT-8 Hot T	opic Symposium
------------	----------------

14:30-16:00 Carron 1/2

ADHD in the classroom

Chairs: J. Swanson, USA

O. Tucha, The Netherlands

HT-8-001 Measuring and quantifying ADHD class-

> room behaviour J. Swanson, USA

HT-8-002 Do what works: Interventions in the class-

room

Y. Groen, The Netherlands

HT-8-003 Neurofeedback and cognitive attention

training for children with ADHD in schools

N. Steiner, USA

HT-9 **Hot Topic Symposium** 

14:30-16:00 Dochart 1/2

Treatment options of adult ADHD

Chairs: A. Philipsen, Germany

C. B. Surman, USA

HT-9-001 Meta-analysis assessing pharmacological

and psychosocial interventions for adults

with ADHD G. Polanczyk, Brazil

HT-9-002 Multimodal treatment of adult ADHD:

A radomized controlled multicentre trial

(COMPAS)

A. Philipsen, Germany

Omega-3 polyunsaturated fatty acids and

other food supplements

K. W. Lange, Germany

RC-3 **Research Consortia Session** 

14:30-16:00 **Boisdale 1** 

Eunethydis consortium: The European guideline groups

Chairs: T. Banaschewski, Germany

D. Coghill, United Kingdom

RC-3-001 New findings from the meta-analyses of

behavioural and cognitive interventions

for ADHD

E. J. S. Sonuga-Barke, United Kingdom

RC-3-002 The psychiatrist's perspective

E. Simonoff, United Kingdom

RC-3-003 The psychologist's perspective

S. van der Oord, The Netherlands

RC-3-004 Can a behavioural sleep intervention im-

prove outcomes for children with ADHD?

A randomised controlled trial

E. Sciberras, Australia

The influence of comorbid ODD on white RC-3-005

> matter microstructure in ADHD H. van Ewijk, The Netherlands

16:00 - 17:00 **Break** 



P-01	Guided Poster Tour	P-02	Guided Poster Tour
16:00-17:30	Hall 2 – Poster Area	16:00-17:30	Hall 2 – Poster Area
Aetiology I Chair:	S. Faraone, USA	Epidemiolog Chair:	gy <mark>l</mark> R. G. Klein, USA
P-01-001	Detection of auto-antibodies to DAT in the serum: Interactions with DAT genotype and psycho-stimulant therapy for ADHD. W. Adriani, Italy E. Romano, M. C. Porfirio, P. Curatolo, G. Laviola	tion and its associa out-patients of Ph Medical Center usir atric symptom check	The prevalence of psychosocial dysfunction and its associated factors among out-patients of Philippine Children's Medical Center using the pictorial pediatric symptom checklist – Filipino version: A cross-sectional study
P-01-002	The relationship between psychological trauma, parenting attitude and Attention-Deficit/Hyperactivity Disorder symptoms	P-02-002	G. A. Divino Lobo, Philippines C. J. Banaag  Providence of Attention Deficit/Hyper
	in Korean children JH. Bae, Republic of Korea S. Park	P-02-002	Prevalence of Attention-Deficit/Hyper- activity Disorder and its associated fac- tors in children attending normal primary school in Western India
P-01-004	Predictors of disorder severity and comorbidity may differ among patients with		D. Ganjiwale, India J. Ganjiwale, B. Sharma, B. Parmar
	ADHD: Data from a tertiary treatment centre N. Demir, Turkey E. Tufan, Z. Topal, U. Savci, M. A. Cansiz, S. Taskiran, E. Demirbas Cakir, B. Semerci	P-02-003	ADHD in adulthood: An Italian overview G. Giupponi, Italy S. Holzer, G. Gatti, E. Duregger, I. Maniscalco, A. Conca
P-01-005	Breastfeeding, protective factor for the development of ADHD A. Fernández Díaz, Spain M. Lado Codesido, M. González Santos	P-02-004	Attention-Deficit/Hyperactivity Disorder (ADHD) and socioeconomic deprivation in the United Kingdom A. Hire, United Kingdom D. Ashcroft, D. Springate, D. Steinke
P-01-006	Low serum sphingolipids in Attention- Deficit/Hyperactivity Disorder (ADHD) M. Henríquez-Henríquez, USA S. Solari, F. Allende, T. Quiroga, B. Kim, T. S. Worgall	P-02-005 The hood R. Ka	The course of ADHD domains during adult- hood: A seven-year follow-up study R. Karam, Brazil D. Rovaris, V. Breda, F. Picon, M. Victor, C. Salgado, E. Vitola, N. Mota, K. Silva, P.
P-01-007	Relation between salivary cortisol level and cognitive impairment in children with		Guimaraes-da-Silva, M. Meller, P. Belmonte-de-Abreu, L. A. Rohde, E. H. Grevet, C. H. Bau
	Attention-Deficit/Hyperactivity Disorder O. Ibrahim, Egypt W. Haggag, K. Abdelmoez, I. Youssef	P-02-006	Knowledge/understanding, perception, and attitude towards Attention-Deficit/ Hyperactivity Disorder among medical
P-01-008	Association between phthalates and externalizing behaviors and cortical thickness in children with Attention-Deficit/Hyperactivity Disorder  BN. Kim, Republic of Korea  J. W. Kim, SC. Cho, T. Kang, S. Lee, J. I. Kim		students at Faculty of Medicine University of Indonesia C. A. Liu, Indonesia T. Wiguna
P-01-009	An association between poor glycemic control among diabetic patients and un- diagnosed adult ADHD E. Merzon, Israel E. Kitai, A. Golan -Cohen		

Friday, 29 May 2015

P-02-007	Difference in estimated prevalence of preschool ADHD depending on cut-off points using a screening tool in a popula- tion sample in Spain J. J. Marín-Méndez, Spain C. Borra-Ruiz, M. J. Alvarez-Gómez, A. Diez-	P-03-005	Video analysis of ADHD symptoms in simulated classrooms L. Hellwig, Germany C. Gawrilow, J. Schmid, U. Dürrwächter, T. J. Renner
	Suarez, P. de Castro-Manglano, M. Vallejo- Valdivielso, C. Soutullo-Esperón	P-03-006	The use of actigraphy in the diagnosis of Attention-Deficit/Hyperactivity Disorder E. Izquierdo Herrero, Spain
P-02-008	Knowledge/understanding, perception and attitude towards Attention-Deficit/ Hyperactivity Disorder among community		S. Alberola López, J. M. Andrés de Llano, J. A. López Villalobos, D. Martín Martínez, C. Alberola López
	members in Indonesia B. J. Murtani, Indonesia T. Wiguna	P-03-007	A continuum paradigm of psychopathology: Narcissism as the core construct of mental illness
P-02-009	Prevalence of restless legs syndrome in adult ADHD and its subtypes M. Snitselaar, The Netherlands		N. Jacir, Jordan A. Abojdei, N. Abaza, R. Salib
	M. Smits, J. Spijker	P-03-008	Overlapping and disease specific aspects of impulsivity in children and adolescents
P-02-010	Mental health problems, bullying experience and expression of suicidal ideation in the ADHD risk group K. Nari, Republic of Korea Y. S. Kwack		with schizophrenia spectrum disorders or Attention-Deficit/Hyperactivity Disorder J. R. M. Jepsen, Denmark J. Rydkjaer, B. Fagerlund, A. K. Pagsberg, B. Glenthoej, B. Oranje
P-03	Guided Poster Tour	P-04	Guided Poster Tour

P-03	Guided Poster Tour	P-04	Guided Poster Tour
16:00-17:30	Hall 2 – Poster Area	16:00-17:30	Hall 2 – Poster Area

#### Diagnosis - children and adolescents I

Chair: A. Warnke, Germany

P-03-001 What is behind "hyperactivity" in child

**psychiatry?**T. Brahim, Tunisia

A. Guedria, R. Ben Moussa, N. Gaddour, S.

Missaoui

P-03-002 Exploring objective measurements of childhood activity and sleep as potential

predictors of childhood emotional and behavioural difficulties at age 11

C. Budd, New Zealand K. Waldie, J. Thompson

P-03-003 Small bugs throw my body

S. Gallego Villalta, Spain

L. Duran Sandoval, C. Bestue Felipe, J. P. Paolini San Miguel, A. Matías Sanfrutos, A. Ortiz Martin, E. Viñuales Luis, I. Martinez

Lausin, P. Bernal Romaguera

Co-morbidity disorders – children and adolescents I

Chairman C. Walling C. Trade al

Chair: S. Walitza, Switzerland

P-04-002 Sleep functioning in children with ADHD predominantly inattentive type and asso-

ciations with internalizing, oppositional, and sluggish cognitive tempo symptoms

S. Becker, USA

L. Pfiffner, M. Stein, G. L. Burns, K. McBurnett

P-04-003 Connection between developmental lan-

guage disorders and ADHD

N. Gaddour, Tunisia

Z. Ghattassi, A. Guedria, R. Bourourou,

M. Attia

P-04-004 Attentional dysfunction and its impact

on reading performance in children with ADHD, dyslexia and the combined

condition

T. Günther, Germany

W. Scharke, J. Horbach, K. Peters, C. Kraatz, B. Herpertz-Dahlmann, K. Konrad, T. Vloet



P-04-005	Relationships between neurodevelop- mental symptoms and gender variance in children M. Hamada, Japan H. Ito, Y. Murayama, M. Katagiri, A. Uemiya, M. Tsujii	P-05-003	Neurophysiological index of alerting and orienting impairment in adults ADHD patients  A. Galvao-Carmona, Spain M. Vázquez-Marrufo, M. CJ Stehle, E. Ahlers, A. H Neuhaus, M. García-Valdecasas
P-04-006	Catatonia in a boy with autism spectrum disorder and Attention-Deficit/Hyper- activity Disorder W. Jaimes-Albornoz, Spain A. Ballesteros-Prado	P-05-004	Do cognitive and neurophysiological impairments on a performance monitoring task distinguish between ADHD persisters and remitters?  G. Michelini, United Kingdom
P-04-007	Child abuse history in parents and the presence of comorbid affective disorders in their offspring with ADHD		G. L. Kitsune, C. H. M. Cheung, D. Brandeis, T. Banaschewski, P. Asherson, G. McLoughlin, J. Kuntsi
	P. Mundo Cid, Spain J. Aguado Gracia, F. Lopez Seco, S. Acosta García, A. M. Gaviria Gomez, E. Vilella, A. Masana Marin	P-05-006	Characteristics of working memory in patients with different early adulthood outcomes of Attention-Deficit/Hyperactivity Disorder L. Sun, People's Republic of China
P-04-008	Neuropsychological and cognitive abilities in ADHD with developmental coordina-		X. Zhao, C. Wang, E. Wang, Y. Wang, Q. Qian
	tion disorder M. G. Melegari, Italy A. Costa, R. Sacco, M. Giallonardo, A. M. Persico	P-05-007	Neural correlates of cognitive reappraisal of negative affect in children with Attention-Deficit/Hyperactivity Disorder V. van Cauwenberge, Belgium K. Hoppenbrouwers, K. Van Leeuwen, J. B. Wiessers
P-05	Guided Poster Tour		R. Wiersema
16:00 – 17:30 Clinical elect Chair:	Hall 2 – Poster Area trophysiology D. Brandeis, Germany	P-05-008	Impaired behavioural post-error re-adaption in adult patients with ADHD S. Deppermann, Germany
P-05-001	A comparison study of the validity of parent- and self-report of ADHD in adolescents and young adults using cognitive, neurophysiological and actigraph correlates  E. Du Rietz, United Kingdom  C. H. M. Cheung, G. McLoughlin, D. Brandeis,	P-05-009	Desynchronization of theta-phase gamma- amplitude coupling appeared during the mental arithmetic task in children with Attention-Deficit/Hyperactivity Disorder J. W. Kim, Republic of Korea Y. S. Lee
	T. Banaschewski, P. Asherson, J. Kuntsi	P-06	Guided Poster Tour
P-05-002	Performance monitoring, response control and post-error adjustments in adults with Attention-Deficit/Hyperactivity Disorder	16:00 – 17:30 Pathophysic Chair:	
	(ADHD): An EEG analysis A. C. Ehlis, Germany S. Deppermann, A. Fallgatter	P-06-001	Decision-making in adults with ADHD D. F. Bangma, The Netherlands J. Koerts, E. Claes, A. B. M. Fuermaier, O. Tucha, L. Tucha

P-06-002	Assessment of the three attentional networks in adult with Attention-Deficit/ Hyperactivity Disorder M. Duarte, Switzerland S. Urben, M. Bader	P-06-012	Emotional-motivational deficits in healthy students with an increase in ADHD symptoms A. Conzelmann, Germany E. Werst, S. Schulz, T. Renner, P. Pauli
P-06-003	Interoceptive ability in adults with ADHD E. Godefroid, Belgium J. R. Wiersema	P-06-013	The comparison of executive functions in different types of Attention-Deficit/ Hyperactivity Disorder (ADHD)
P-06-004	Skin conductance measured arousal shares familial influences with reaction time vari- ability in ADHD S. James, United Kingdom C. Cheung, F. Rijsdijk, P. Asherson, J. Kuntsi	P-06-014	H. Sabery, Iran M. Honjani  Differential attentional impairments in adult ADHD S. Salomone, United Kingdom
P-06-005	Looking into the eye of Attention-Deficit/ Hyperactivity Disorder – first data on pho- tophobia in adults with ADHD		G. R. Fleming, J. Bramham, R. G. O´Connell, I. H. Robertson
	S. Kooij, The Netherlands D. Bijlenga	P-07	Guided Poster Tour
	, -	16:00-17:30	Hall 2 – Poster Area
P-06-006	Interoceptive awareness in patients with Attention-Deficit/Hyperactivity Disorder K. Kutscheidt, Germany	Neuroimagir Chair:	ng I K. Rubia, United Kingdom
	T. Ethofer, A. J. Fallgatter, AC. Ehlis	P-07-001	The executive functions regulated by COMT Val158Met (rs4680) genotype were
P-06-007	Attention to dopamine-dopaminergic dysfunction, a study on adult ADHD and schizophrenia J. Le Sommer, Denmark AM. Low, T. Habekost, J. R. Møllegaard Jepsen, B. Yding Glenthøj, B. Oranje		divergent in children with Attention- Deficit/Hyperactivity Disorder and healthy controls J. Jin, People's Republic of China L. Liu, Q. Gao, R. C. K. Chan, H. Li, Y. Chen, Y. Wang, Q. Qian
P-06-008	Slow learning pattern in risk selection process in adolescents with Attention- Deficit/Hyperactivity Disorder E. Medrano, Mexico J. C. Flores, H. Nicolini	P-07-002	NIRS findings in adults with ADHD Y. Okajima, Japan T. Morita, T. Tokumasu, N. Saga, B. Yamagata, A. Iwanami
P-06-010	Risk taking among people with ADHD – risk seeking or non-optimal decision-making? Y. Pollak, Israel L. Kitrossky, H. Raber	P-07-003	Distinct categorical and dimensional neural correlates across functional brain networks in ADHD R. Pruim, The Netherlands C. Beckmann, J. Buitelaar, M. Mennes
P-06-011	Intra-subject variability of ocular motor responses in patients with ADHD and typical controls Y. Schulz-Zhecheva, Germany	P-07-004	A critical review of Magnetic Resonance Spectroscopy (MRS) studies on ADHD A. Reid, United Kingdom
	M. Völkle, B. Feige, C. W. N. Saville, M. Biscaldi, C. Klein	P-07-005	Emotional recognition and white matter abnormalities in ADHD-I A. Rossi, Brazil V. Hermann, M. V. Alves, C. Mello, O. Bueno



P-07-006	An fMRI study on neural systems for empathy in ADHD JW. Son, Republic of Korea JE. Kim	P-08-003	Biofeedback training in school children with Attention-Deficit/Hyperactivity Disorder (ADHD): Differential effects of a training in a 2D or 3D environment F. Blume, Germany
P-07-007	Altered serotonin transporter bind- ing in patients with Attention-Deficit/ Hyperactivity Disorder / Investigated with		J. Hudak, T. Dresler, T. Renner, C. Gawrilow, AC. Ehlis
	PET and [11C]DASB T. Vanicek, Austria A. Kutzelnigg, H. L. Sigurdardottir, A. Hahn, G. S. Kranz, M. Spies, A. Kautzky, D. Haeusler, T. Traub-Weidinger, M. Hacker, M. Mitterhauser, W. Wadsak, S. Kasper,	P-08-004	Behavioural parent training (BPT) group for children with ADHD: Improvement in functional and clinical symptoms C. Boix, Spain A. Palacio, R. Colome, A. Lopez-Sala, A. Sans-Fito
P-07-008	R. Lanzenberger  Laterality of activation patterns in boys with Attention-Deficit/Hyperactivity Disorder and effects of methylphenidate during verbal working memory task Z. Wu, People's Republic of China M. Hoogman, Q. Cao, L. An, L. Yang, J.	P-08-005	A novel (pilot) intervention group for parents of children with comorbid ASD and ADHD-showing positive effects on stress levels and ability to manage chil- dren better M. Digiuni, United Kingdom O. Moghraby, J. Mueller, K. Kwan
	Bralten, L. Liu, L. Sun, Q. Qian, B. Franke, Y. Wang	P-08-006	Improving executive functioning in children with ADHD: Training multiple ex-
P-07-009	Frequency-specific abnormalities in regional homogeneity among children with Attention-Deficit/Hyperactivity Disorder: A resting-state fMRI study X. Yu, People's Republic of China B. Yuan, Q. Cao, L. An, P. Wang, A. Vance,		ecutive functions within the context of a computer game. Moderators of outcome in a randomized double-blind placebo controlled trial S. Dovis, The Netherlands S. Van der Oord, R. Wiers, M. Marija, P. Prins
	T. J. Silk, Y. Zang, L. Sun, Y. Wang	P-08-007	Comparison of neurofeedback training and working memory training of chil-
P-08	Guided Poster Tour		dren who have a non-medicated ADHD.  A pilot study, with neuropsychological
16:00-17:30	Hall 2 – Poster Area		assessment, questionnaires, and QEEG as
	acological treatment–children and		effect measurements S. Einarsdottir, Norway
adolescents Chair:	HC. Steinhausen, Denmark		H. M. Taklo, K. Instebø, D. Socanski, M. Bremnes, H. Beneventi
P-08-001	Cognitive remediation for adolescents with attention disorder with or without hyperactivity/impulsivity: Neuropsychological aspects S. Ackermann, Switzerland S. Urben, E. Fornari, S. Leopizzi, O. Halfon, M. Bader	P-08-008	Implementing computer-based working memory training in a regular classroom setting. A pilot study, with reading and arithmetic performance tests as effect measurements  K. Instebø, Norway
P-08-002	Digital technologies and cyberculture in in-patient psychiatric treatment of adolescents with severe ADHD – a tech- nology-based therapeutic and pedagogic intervention (SOMOSA MedialabR) O. Bilke-Hentsch, Switzerland M. Hartmann	P-08-009	S. Einarsdottir, H. M. Taklo, D. Socanski, M. Bremnes, H. Beneventi  Protocol for the Sheffield Treatments for ADHD Research (STAR) project: Testing the feasibility of the trial design P. Fibert, United Kingdom C. Relton

Friday, 29 May 2015

P-08-010 The use of mindfulness mediation and P-09-008 Addressing disparities between Latinos and emotion regulation for children with non-Latinos accessing a school-home col-ADHD laborative behavioral treatment for ADHD N. Leventhal, Canada L. Haack, USA E. A. Araujo, M. Capriotti, A. Beaulieu, D. Almagor, D. Almagor K. McBurnett, L. Pfiffner P-09-009 Listening therapy as a non-pharmacolo-P-09 **Guided Poster Tour** gical treatment, which can reduce ADHD 16:00-17:30 Hall 2 - Poster Area symptoms in children Non-pharmacological treatment-children and S. Kashirina, Russia adolescents II Y. Golubeva Chair: M. Solanto, USA P-09-001 Assessing the effectiveness of the P-10 **Guided Poster Tour** 'Incredible Years(®) parent training' to 16:00-17:30 Hall 2 - Poster Area parents of schoolage children with ADHD A. Kerridge, Canada Pharmacological treatment-children and K. Dawson, S. Schmiedel, M.-P. Vandette, adolescents I G. Kohls, Germany P. Robaev Chair: Effects of brain-computer interface-based P-09-002 P-10-001 Population pharmacokinetics models to attention training programme for ADHD guide prescription combining immediate X. Lee, Singapore and modified-release methylphenidate D. S. Sheng Fung, R. Phillips, C. Guan, T.-S. G. Bonnefois, Canada Lee, C. G. Lim P. Robaey, O. Barrière, J. Li, F. Nekka Emotion control in children with ADHD. P-09-003 P-10-002 ADHD stimulant response. Clinical predicexamination of self-report, observational, tion research and physiological components L. Duño-Ambros, Spain S. Li-Yu, Taiwan E. Pujals-Altés, X. Estrada-Prat, M. T. Nascimento-Osorio, A. Petrizan-Aleman, S. P-09-004 Implementation evaluation of a social Batlle Vila, E. Baeza-Tena, E. Camprodon skills training programme for children Rosanas, V. Perez-Sola, L. M. Martin-Lopez with ADHD in school, community and child psychiatry clinic settings P-10-003 Behavioural investigation of the effect of L. Massé, Canada methylphenidate among children with C. Verret ADHD in Taiwan: A preliminary study S.-J. Hung, Germany P-09-005 The WHAAM application: An evidence-C.-M. Yu, M.-H. Hsieh, C. Gawrilow, S. based application to support behavioural S.-Fen Gau interventions G. Merlo, Italy P-10-004 Nationwide data for short- and long-term C. Giuseppe, M. Sanches-Ferreira, C. McGee, medication compliance of ADHD in Korea G. Doherty, D. Spachos M. Hong, Republic of Korea J. Han, G. H. Bahn, B. Kim, J.-W. Hwang, H.-Y. P-09-006 The role of group parent education on Choi, I. H. Oh, Y. J. Lee medication adherence in children with Attention-Deficit/Hyperactivity Disorder P-10-005 Clinical efficacy of guanfacine extended H. Gao, People's Republic of China release among children with primarily D. Zhu inattentive subtype of Attention-Deficit/ Hyperactivity Disorder: Results from P-09-007 Tomatis method as a therapy for children 3 studies in four phases and adults which can improve the quality M. Huss, Germany of life of ADHD people K. McBurnett, A. Cutler, A. Hervas, B. Adeyi, S. Kashirina, Russia B. Dirks Y. Golubeva



P-10-006	Efficacy and tolerability of lisdexamfetamine (LDX) in children and adolescents with Autism Spectrum Disorders (ASD) and Attention-Deficit/Hyperactivity Disorder (ADHD) symptoms W. Jaimes-Albornoz, Spain	P-11-002 P-11-004	Sleep problems in ADHD youth before and during treatment with methylphenidate and atomoxetine M. Stein, USA M. Garison, A. Hart, J. Newcorn Outcome of ADHD treatment in young
P-10-007	A. Ballesteros-Prado  Cost-effectiveness of guanfacine extended- release for the treatment of children	r-11-00 <del>4</del>	people age 14 – 18 years I. Takon, United Kingdom S. Ozer, A. Khan, R. Beets, M. Atherton
	and adolescents with Attention Deficit Hyperactivity Disorder (ADHD) in the UK A. Joseph, Switzerland J. Xie, E. Wu, V. Sikirica	P-11-005	Randomized, double-blind, active- and placebo-controlled trials of lisdexamfe-tamine dimesylate in adolescents with Attention-Deficit/Hyperactivity Disorder
P-10-008	Interaction between dopaminergic genotypes and frontostriatal volumes predicting methylphenidate response in		J. Newcorn, USA P. Nagy, A. Childress, G. Frick, B. Yan, L. Politza, S. Pliszka
	Attention-Deficit/Hyperactivity Disorder BN. Kim, Republic of Korea J. W. Kim, SC. Cho	P-11-006	ADHD medication prescribing among young people with ADHD in the clinical practice research datalink 2005-2013:
P-10-009	Factors related to a lower response to methylphenidate in a continuous performance test (CPT) evaluation  N. Lourenço, Portugal		Analysis of time to cessation T. Newlove-Delgado, United Kingdom T. Ford, W. Hamilton, K. Stein, O. C. Ukoumunne
	J. Boavida Fernandes, M. Jerónimo, C. A. Alfaiate, M. Almeida, S. Nogueira, M. J. Seabra Santos, J. Boavida Fernandes	P-11-007	Objective evaluation of ADHD in special needs settings-explicating clinical outcomes
P-10-010	Milnacipran and atomoxetine in the treatment of adolescents with Attention-Deficit/Hyperactivity Disorder		S. Perera, United Kingdom J. Kaleyias
	I. Martsenkovsky, Ukraine M. Inna	P-11-008	<b>Digital follow-up for children with ADHD</b> E. Posener, Israel
		P-11-009	Association of DAT1 gene and clock gene (T3111C) genotypes, family functioning,
P-11	Guided Poster Tour		parental psychopathology and treatment
16:00-17:30			response in ADHD adolescents F. Delapena, Mexico
Pharmacolog adolescents Chairs:	gical treatment–Children and II J. Buitelaar, The Netherlands		D. Guizar, L. Palacios, C. Cruz, V. Perez
Cildiis.	J. Buitelaar, The Netherlands		
P-11-001	A phase 2 pharmacokinetic study of a modified release formulation of dextro-amphetamine following evening administration to adolescents and children with ADHD  D. Quinn, Canada T. Bode, B. DeSousa, B. Incledon, A. McLean, D. Lickrish		

P-12	Guided Poster Tour	P-13	Guided Poster Tour
16:00-17:30	Hall 2 – Poster Area	16:00-17:30	Hall 2 – Poster Area
Pharmacolog Chair:	gical treatment – adults I M. Rösler, Germany	Pharmacolog Chair:	gical treatment – adults II C. B. Surman, USA
P-12-001	Predictors of response to atomoxetine for the treatment of adult patients with Attention-Deficit/Hyperactivity Disorder C. Bushe, United Kingdom E. Sobanski, D. Coghill, L. Berggren, K. De Bruyckere, S. Leppämäki	P-13-001	Real-world treatment outcomes in adults with Attention-Deficit/Hyperactivity Disorder treated with lisdexamfetamine versus atomoxetine following methylphenidate treatment  A. Joseph, Switzerland  M. Cleating A. Charin R. Nitulescu V. Sikirica
P-12-002	Effects of atomoxetine on functional outcomes, and correlation with the core symptoms of Attention-Deficit/ Hyperactivity Disorder in adult patients K. de Bruyckere, Belgium C. Bushe, C. Bartel, L. Berggren, C. C. Kan, S. Stes, R. W. Dittmann	P-13-002	M. Cloutier, A. Guerin, R. Nitulescu, V. Sikirica  Complications in a case of adult ADD: Bupropion-induced seizure and a MRI- finding M. Koelle, Germany G. Groen, N. Kahn, D. Brummer
P-12-003	Our experience with lisdexamfetamine dimesylate in Southern Spain M. A. Fernández Fernández, Spain M. D. Morillo rojas	P-13-003	Monitoring dose effects of stimulant medication with AQT processing speed in adults with ADHD N. P. Nielsen, Denmark E. H. Wiig, S. Bäck, G. Ege, J. Gustafsson, C. Hornborg, G. Magell
P-12-004	Integrated diagnosis and treatment of adults with Attention-Deficit/Hyperactivity Disorder (IDEA) R. Fischer, Germany M. Rösler, W. Retz	P-13-004	Eye movements: Good marker of methylphenidate efficiency in ADHD M. Seassau, France F. Duval, A. Erb, T. Weiss, R. Carcangiu
P-12-005	Adult ADHD treated with methylphenidate modified-release (MPH-LA) maintained functional improvement over a period of one year M. Huss, Germany Y. Ginsberg, T. Arngrim, A. Philipsen, P. Gandhi, Cw. Chen, V. Kumar	P-13-005	Long-term open-label treatment with atomoxetine in European adult outpa- tients with Attention-Deficit/Hyperactivity Disorder H. Upadhyaya, USA Y. Tanaka, D. Williams, R. Escobar, S. Leppämäki
P-12-006	Long-term safety of methylphenidate modified-release in adult ADHD upon continuous exposure up to 66 weeks	P-13-006	Off-Label use of guanfacine XR in adult ADHD: A clinical experience A. Vincent, Canada
	M. Huss, Germany Y. Ginsberg, T. Arngrim, A. Philipsen, P. Gandhi, Cw. Chen, V. Kumar	P-13-007	Continuity of treatment with methylphenidate in adults with ADHD after seven years V. Breda, Brazil R. Karam, D. Rovaris, F. Picon, M. Victor, C. Salgado, E. Vitola, N. Mota, K. Silva, P. Guimaraes-da-Silva, M. Meller, P. Belmontede-Abreu, L. Rohde, E. Grevet, C. Bau



P-14	Guided Poster Tour	P-14-011	The link between sleep difficulties, social
16:00-17:30	Hall 2 – Poster Area		functioning in school and ADHD severity M. Efron, Israel
Quality of lift Chair:	e/caregiver burden I D. Silva, Australia	P-14-012	T. Harel, M. Bar, D. Gothelf, j. Kushnir  Mental health of parents of children with
P-14-002	Self concept and quality of life in children with ADHD M. Almeida, Portugal J. Boavida Fernandes, A. R. Fernandes, C. Alfaiate, S. Nogueira, M. J. Seabra Santos		Attention-Deficit/Hyperactivity Disorder in comparison with parents of children with other developmental disabilities T. Takamura, Japan
P-14-004	Healthcare use in children with Attention- Deficit/Hyperactivity Disorder (ADHD) in France: Results from the QUEST survey H. Caci, France D. Cohen, O. Bonnot, B. Kabuth, JP. Raynaud, S. Paillé, L. Vallée	P-14-013	Is impulsive buying behaviour associated with traits of ADHD in an adult community sample?  D. F. Bangma, The Netherlands  J. Koerts, A. B. M. Fuermaier, O. Tucha, L. Tucha
P-14-005	Voices of experience: A qualitative study	P-15	Guided Poster Tour
	of stress, emotion, and coping in the lived experiences of children with ADHD	16:00-17:30	Hall 2 – Poster Area
	K. Carr-Fanning, United Kingdom	Quality of line Chair:	fe/caregiver burden II J. Thome, Germany
P-14-006	Mother-child relationship in siblings of adolescents with Attention-Deficit/ Hyperactivity Disorder (ADHD) J. PChen Chang, Taiwan S. SFen Gau	P-15-001	Teacher supervision in children with ADHD: A classroom observation study L. Imeraj, Belgium I. Antrop, E. Sonuga-Barke, H. Roeyers
P-14-007	The impact of comorbid conditions on caregivers' work, social and family activities: Results from the caregiver perspective on pediatric ADHD (CAPPA) study in Europe K. Chen, USA M. Fridman, J. Quintero, V. Harpin, T. Bana-	P-15-002	Longitudinal effect of Attention-Deficit/ Hyperactivity Disorder symptoms on social relationship H. Ito, Japan M. Hamada, A. Uemiya, Y. Murayama, M. Katagiri, M. Tsujii
P-14-008	schewski, M. H. Erder, V. Sikirica  Risky sexual behaviour adolescents with ADHD-undervalued source problems M. Dabkowski, Poland M. Dabkowska	P-15-003	Protective mechanisms related with resilience process in children with Attention Deficit/Hyperactivity Disorder A. M. Jurma, Romania D. L. Morariu
P-14-009	Costing adult Attention-Deficit/Hyperactivity Disorder: Impact on the individual and society D. Daley, United Kingdom R. H. Jacobsen Højbjerg Jacobsen, A. Mette-Lange, J. Walldorf, A. Sørensen	P-15-005	Lifetime victimization in children and adolescents with ADHD F. Lopez Seco, Spain A. Masana Marin, J. Aguado Gracia, P. Mundo Cid, S. Acosta García, A. M. Gaviria Gómez, E. Vilella
P-14-010	ADHD coaching with college students: Implications for practice S. Diers, USA F. Prevatt, S. Smith, D. Marshall, J. Coleman, E. Valler, N. Miller, J. Belle	P-15-006	ADHD and perceived job competence: The role of positive illusionary bias G. Mackenzie, Canada R. Martinussen, M. Aitken

P-15-007	Psycho-education for ADHD medication initiation for children and adolescents in a London borough: An innovation and improvement project O. Malomo, United Kingdom O. Moghraby	P-16-003	Association between genetic variants of NET1 and emotional lability of ADHD independent of ODD diagnosis or ODD symptoms L. Liu, People's Republic of China L. Sun, X. Yu, H. Li, L. Yang, Q. Qian, Y. Wang
P-15-008	LINK: The adult Attention-Deficit/Hyper- activity Disorder programme (ADHD): Connecting-educating-advancing (Part II) L. Klassen, Canada A. Fallu	P-16-004	Dopamine transporter (DAT1) and dopamine receptor (DRD4) genotype and response to methylphenidate and atomoxetine  M. Stein, USA
P-15-009	A clinical audit of transitional care in adolescents with ADHD at Blakesley Centre		T. Hildebrandt, E. Cook Jr, E. Olson, I. Waldman, J. Newcorn
	CAMHS J. Holmes, United Kingdom E. Loh	P-16-005	Hyper-locomotor activity in mice lacking in an enzyme synthesizing chondroitin sulfate as an animal model of ADHD
P-15-010	Medication non-adherence, symptom worsening and relapse, and their impli-		M. Igarashi, Japan N. Yoshioka, K. Takeuchi, K. Takao, T. Mi- yakawa
	cations for health-related quality of life in the treatment of Attention-Deficit/ Hyperactivity Disorder(ADHD) in Non- Western countries J. Hong, United Kingdom D. Novick, T. Treuer, W. Montgomery, J. M. Haro	P-16-006	Shared prefrontal cortical gene expression profiles in "impulsive" SHR and Wistar rats: Effects of atomoxetine J. B. de La Pena, Republic of Korea H. J. Kim, I. dela Pena, C. Y. Shin, J. H. Cheong
P-15-012	Mental health of parents of children with Attention-Deficit/Hyperactivity Disorder in comparison with parents of children with other developmental disabilities T. Takamura, Japan	P-16-007	Unravelling the effect of methylphenidate on human brain endothelial cells V. Santos, Portugal R. Socodato, C. Portugal, M. Rito, M. Barbosa, PO. Couraud, I. A. Romero, B. Weksler, R. Minshall, C. Fontes-Ribeiro, T. Summavielle, J. B. Relvas, A. P. Silva
P-16	Guided Poster Tour	P-16-008	Expressional profile in fibroblasts of PARK2
16:00-17:30		1 10 000	CNV carriers with adult ADHD
Chair:	e/genetics/experimental models  B. Franke, The Netherlands		S. Kittel-Schneider, Germany D. Gersic, M. Frank, C. Lorenz, J. Auer, KP. Lesch, S. Winkler, S. Klebe, A. Reif
P-16-001	Which parameters differ in the gait of children with ADHD? H. Naruse, Japan C. Yatsuga, T. Fujisawa, H. Kumazaki, S. Takiguchi, H. Matsuo, M. Kubota, S. Shimada, D. Saito, H. Kosaka, A. Tomoda	P-16-009	Transcranial direct current stimulation improves short-term memory in an animal model of Attention-Deficit/Hyperactivity Disorder  D. Teixeira Leffa, Brazil
P-16-002	No association of ADHD candidate SNPs with Parkinson's disease J. Geissler, Germany M. Romanos, M. Gerlach		V. Scarabelot, A. de Souza, L. Fernandes Medeiros, E. Horácio Grevet, D. Onofre Gomes de Souza, L. A. Paim Rohde, I. Lucena da Silva Torres, C. de Oliveira



Friday, 29 May 2015

P-16-010 Exposure to acetaminophen during development does not induce hyperactivity in zebrafish larvae

C. Drepper, Germany

M. Romanos

P-16-011 The impact of teaching problem solving skills on the social skills of children with

ADHD

M. Shokoohi-Yekta, Iran

S. Alimohammadi Malayeri, S. Salem

P-16-012 The effectiveness of teaching problem solving skills on the symptoms of

M. Shokoohi-Yekta, Iran

S. Alimohammadi Malayeri, A. Parand,

Attention-Deficit/Hyperactivity Disorder

S. Salem

P-16-013 Psychohistory: What can we learn about

ADHD from the Old Testament?

E. Merzon, Israel

T. Merzon, E. Kitai, A. Gola-Cohen

ES-1 Educational Seminar

Organisation and carrying out of parent training in ADHD

ES-1-001 Organisation and carrying out of parent

training in ADHD

C. Neuhaus, Germany

ES-2 Educational Seminar

17:00 – 18:00 O Alsh 1/2

Ambulatory assessment to study ADHD patients in their natural environment

ES-2-001 Ambulatory assessment to study ADHD

patients in their natural environment

C. Gawrilow, Germany F. Schmiedek, Germany

ES-3 Educational Seminars

17:00 – 18:00 Olyde Auditorium

New assessment strategies of ADHD in adults

ES-3-001 New assessment strategies of ADHD in

adults

A. Philipsen, Germany W. Retz, Germany

ES-4 Educational Seminar

17:00-18:00

To treat or not to treat—controversies and difficulties related to treatment of this population—psychosocial treatment, what do we know?

ES-4-001 Treatment of ADHD and substance abuse

J. A. Ramos-Quiroga, Spain G. van de Glind, The Netherlands

Lomund Auditorium

O Boisdale 1

O Dochart 1/2

ME-1 Meet-the-Expert Session

17:00-18:00

Diagnosis of ADHD

ME-1-001 Diagnosis of ADHD

L. A. Rohde, Brazil

ME-2 Meet-the-Expert Session

ADHD over the lifetime

17:00-18:00

ME-2-001 ADHD over the lifetime

R. G. Klein, USA

ME-3 Meet-the-Expert Session

In the second of ADID and the second of the

New advances in ADHD genetics and how they might inform clinical practice

ME-3-001 New advances in ADHD genetics and how

they might inform clinical practice

T. Banaschewski, Germany

Saturday, 30 May 2015

08:30-10:30 Clyde Auditorium New advances in ADHD neurobiology Chairs: T. Banaschewski, Germany M. Gerlach, Germany New advances in the neurobiology of PL-2-001 Attention-Deficit/Hyperactivity Disorder S. Faraone, USA PL-2-002 25 years of neuroimaging: Progress towards understanding the pathophysiology of ADHD F. X. Castellanos, USA PL-2-003 Frontiers in the neuropsychology of Attention-Deficit/Hyperactivity Disorder: Seven important themes E. J. S. Sonuga-Barke, United Kingdom

**Plenary Session** 

10:30 – 11:00 Break

K.-P. Lesch, Germany

Translating genetics findings into biologi-

cal mechanisms for ADHD through animal

PL-3 Plenary Session

models

PL-2

PL-2-004

11:00–12:30 Clyde Auditorium

Role play clinical interview: An ADHD evaluation of young John F. Kennedy

Moderator: L. A. Rohde, Brazil Interviewer: T. Brown, USA

Interview with Young JFK: A Bright, but Struggling Student with ADHD?

An anachronistic clinical interview of JFK at age 18 years. This role play will illustrate an approach to evaluation of a very bright adolescent whose chronic struggles in high school might be due to ADHD and/or emotional issues. Actor Ronald Woodhead as JFK is interviewed by Thomas E. Brown, Ph.D. Discussion of implications for current practice will follow.

12:30 – 14:30 Lunch Break

SA-02 Industry Sponsored Symposium

12:45 – 13:45 Forth Room

please see page 53

HT-10 Hot Topic Symposium

14:30 – 16:00 Forth room

Towards an evidence-based taxonomy of non-pharmacologic treatments for ADHD

Chairs: S. Faraone, USA

J. Buitelaar, The Netherlands

HT-10-001 Integrating pharmacologic and non-phar-

macologic treatments: An evidence-based

approach, is that OK? S. Faraone, USA

HT-10-002 Self-help interventions for ADHD

M. Döpfner, Germany

HT-10-003 Lifestyle interventions for ADHD

J. Halperin, USA

HT-10-004 Cognitive training for ADHD: Results,

**problems and prospects**J. Buitelaar, The Netherlands

HT-11 Hot Topic Symposium

14:30 – 16:00 Lomund Auditorium

Recent data from adult ADHD follow-up studies

Chairs: J. Biederman, USA

G. Polanczyk, Brazil

HT-11-001 Persistence and remission of ADHD dur-

ing adulthood: A 7-year clinical follow-up

study

C. Bau, Brazil

HT-11-002 Lacking evidence that DSM-5 adult ADHD

is a childhood-onset neurodevelopmental disorder: A 4-decade longitudinal cohort

study

G. Polanczyk, Brazil

HT-11-003 Predictors of outcome at age 41 among

8 year olds with ADHD

R. G. Klein, USA

HT-11-004 Functional MRI findings on persistence of

ADHD from childhood onto adulthood

J. Biederman, USA



HT-12	Hot Topic Symposium	HT-14	Hot Topic Symposium
14:30-16:00	0 Alsh 1/2	14:30-16:00	0 Dochart 1/2
Early life fac Chairs:	ctors as origin of ADHD  B. van den Bergh, The Netherlands  C. Tiesler, Germany		akefulness regulation: A common patho- tor in ADHD and manier  U. Hegerl, Germany
HT-12-001	Prenatal maternal anxiety and ADHD- related behaviour and cognitive task performance in the adolescent offspring B. van den Bergh, The Netherlands	HT-14-001	M. Romanos, Germany  The noradrenergic neurotransmitter system in ADHD  T. Vanicek, Austria
HT-12-002	Perinatal exposure to nicotine and tobacco smoke in relation to the onset of ADHD	HT-14-002	Vigilance regulation in adult ADHD M. Strauß, Germany
HT-12-003	C. Tiesler, Germany  Maternal alcohol consumption during pregnancy and childhood hyperactivity/ inattention  K. Sayal, United Kingdom	HT-14-003	Results of the international multicentre iSPOT-A study in ADHD: EEG predictors of treatment outcome to methylphenidate M. Arns, The Netherlands
HT-12-004	Perinatal exposure to persistent organic pollutants and metals and ADHD T. I. Halldórsson, Iceland	HT-14-004	The effects of stimulant medication or vigilance regulation in childhood ADHD J. Geissler, Germany
		HT-15	Hot Topic Symposium
HT-13	Hot Topic Symposium	14:30 – 16:00	0 Boisdale 1
14:30 – 16:00 Neurobiolo treatment Chairs:	gical mechanisms underlying drug in ADHD U. Müller, United Kingdom	Dopaminers motor disor Chairs:	gic motor behavioural and behavioural eders P. Riederer, Germany E. Wolters, The Netherlands
HT-13-001	J. Newcorn, USA  The effects of stimulant and non-stimulant medication on the ADHD brain	HT-15-001	Iron deficiency, sleep disturbances, dopa- mine and ADHD M. Youdim, Israel
HT-13-002	K. Rubia, United Kingdom  Nigro-striatal mechanisms underlying ADHD and its treatment with methyl- phenidate U. Müller, United Kingdom	HT-15-002	ADHD altered dopamine neurotrans- mission and disrupted reinforcement processes: Implications for smoking and nicotine dependence S. H. Kollins, USA
HT-13-003 Dopamine transporter genotype and dose-response following treatment	Dopamine transporter genotype and dose-response following treatment with psychostimulants: Implications for	HT-15-003	Dopamine dysregulation syndrome, and impulse control disturbances E. Wolters, The Netherlands
	optimization of acute and longer-term treatment J. Newcorn, USA	HT-15-004	Dopamine dysfunctions in motor abnormalities linked to neurological diseases and psychiatric disorders P. Riederer, Germany

16:00 – 16:30 Break		P-17-009	Level of polyunsaturated fatty acids and
P-17	Guided Poster Tour		glutathione peroxidase activity in chil- dren with Attention-Deficit/Hyperactivity Disorder
16:00-17:30	Hall 2 – Poster Area		H. Azouz, Egypt A. Kitat
Aetiology II Chair:	KP. Lesch, Germany		
P-17-001	Mental health in refugee families: Child- hood abuse as a cause of ADHD D. Martsenkovskyi, Ukraine I. Martsenkovsky	P-18	Guided Poster Tour
		16:00 – 17:30 Epidemiolog Chair:	
P-17-002	Life events in the first trimester of pregnancy are related to a poor pregnancy outcome in mothers of ADHD children. F. Lopez Seco, Spain P. Mundo Cid, J. Aguado Gracia, S. Acosta García, A. Masana Marin	P-18-002	Reproductive outcomes of women treated with stimulant medication for Attention-Deficit/Hyperactivity Disorder (ADHD) A. Poulton, Australia R. Nanan
P-17-004		P-18-003	Socioeconomic associations with ADHD: Findings from a mediation analysis A. Russell, United Kingdom T. Ford, G. Russell
		P-18-004	Prevalence of ADHD subtypes, risk factors and relation to sluggish cognitive tempo symptoms in school children in Crete, Greece M. Skounti, Greece E. Aifanti, E. Parlama, M. Kouvidi, P. Skounti
P-17-005	Evidence for a bias towards virtual navigation response strategies in 8-year old children with ADHD symptoms P. Robaey, Canada S. McKenzie, R. Schachar, M. Boivin, V. Bohbot	P-18-005	Mothers with ADHD: Clinical characteristics, comorbidity and treatment history M. Stein, USA J. Strickland, A. Chronis-Tuscano
P-17-006	Comorbidity of allergic diseases among patients with ADHD and Tourette's disorder: A nationwide population-based study J. H. Son, Republic of Korea Y. S. Lee, J. Han, G. H. Bahn	P-18-006	Knowledge and attitudes towards Attention-Deficit/Hyperactivity Disorder (ADHD): A cross-cultural comparative study between Scotland and Romania M. Toma, United Kingdom
P-17-007	Circadian rhythm disruption as a link between Attention-Deficit/Hyperactivity Disorder and obesity? S. Vogel, The Netherlands D. Bijlenga, M. Tanke, T. Bron, K. van der Heijden, H. Swaab, A. Beekman, S. Kooij	P-18-007	Knowledge/understanding, perception, and attitude towards Attention-Deficit/ Hyperactivity Disorder (ADHD) among general practitioners in Jakarta J. A. Wibowo, United Kingdom T. Wiguna
P-17-008	Serum ferritin is negatively correlated with inattention in a sample of Egyptian children with Attention-Deficit/Hyperactivity Disorder M. Seleem, Egypt T. El-Gohary, M. Eid, E. Sroor	P-18-008	The first follow-up study of Attention-Deficit/Hyperactivity Disorder from China Q. Gao, People's Republic of China Y. Qian, X. He, W. Chang, Y. Li, Q. Cao, Y. Wang, Q. Qian



P-19	Guided Poster Tour	P-19-008	Diagnostic efficiency of the SDQ total
16:00–17:30 Hall 2 – Poster Area  Diagnosis – Children and adolescents II  Chair: M. Romanos, Germany			difficulties and hyperactivity/inattention subscales in the UK: A ROC analysis G. Perez Algorta, United Kingdom E. A. Youngstrom, A. Stringaris
P-19-001	Review of clinical guidelines for children and adolescents with Attention-Deficit/ Hyperactivity Disorder and their applica- tion to an Irish context G. Kavanagh, Ireland S. O'Hanrahan, G. Hughes, F. McNicholas	P-19-010	The utilization of d-CPT test in differentiation of Attention-Deficit/Hyperactivity Disorder and anxiety disorders in children S. Taskiran, Turkey B. Semerci, I. Sanli, A. Ozcan
P-19-002	Specificity of temper tantrums in children with Attention-Deficit/Hyperactivity Disorder J. Maire, France C. Galera, S. Bioulac, M. Bouvard, G. Michel	P-20	Guided Poster Tour
		<b>16:00 – 17:30 Diagnosis – a</b> Chair:	
P-19-003	Neuropsychological measures in the diagnosis of ADHD in preschool J. Merkt, Germany M. Siniatchkin, F. Petermann	P-20-001	Influence of depressive symptoms on Qb test performance in adult ADHD patients S. Fischer, Germany M. Köber, H. Lehfeld, G. Niklewski, C. Brandl
P-19-004	Relations of hyperactivity/impulsivity and other behaviour problems in children M. Oros, Serbia I. Jerkovic	P-20-003	Detection of feigned adult ADHD A. B. M. Fuermaier, The Netherlands L. Tucha, J. Koerts, Y. Groen, J. Thome, O. Tucha
P-19-005	Diferential diagnosis between Juvenil Huntington disease and Attention-Deficit/ Hyperactivity Disorder. Case report J. Paolini, Spain S. Gallego, P. Bernal, I. Martinez, L. Nikov, E. Mayayo, C. Bestue, L. Duran, M. Serrano,	P-20-004	Comparison between ADHD and depressive adult outpatients: Emotional dysregulation and impulsivity I. Javier, Spain M. María, B. José Ma
A. Matias  P-19-006 Latent class analysis of Attention-D Hyperactivity Disorder (ADHD) symp		P-20-005	Validity of screening instruments of adult Attention-Deficit/Hyperactivity Disorder H. Kim, Republic of Korea YJ. Lee, DH. Song, KA. Cheon
	with Korean children and adolescents K. J. Park, Republic of Korea	P-20-006	Cognitive functioning in adult Attention- Deficit/Hyperactivity Disorder (ADHD) AM. Low, Denmark
P-19-007	Diagnostic efficiency of the CASI-4 ADHD subscales in the LAMS study: A ROC analysis G. Perez Algorta, United Kingdom E. A. Youngstrom, A. van Meter, L. E. Arnold, M. A. Fristad, S. M. Horwitz, T. W. Frazier, H. Taylor, R. L. Findling	D 20 007	J. le Sommer, J. R. Møllegaard Jepsen, S. Vangkilde, T. Habekost
		P-20-007	Pay time and attention to adult ADHD E. Protti, Italy P. Negro

P-20-008	Reflection on the clinical profile of late onset and undiagnosed adult ADHD D. Roy, United Kingdom	P-21-002	How does comorbidity affect neuropsy- chological test performance in youth with ADHD: Single-centre, cross-sectional study I. Sanli, Turkey E. Tufan, S. Taskiran, B. Semerci, M. A. Cansiz, U. Savci, N. Demir, Z. Topal
P-20-009	A heuristic perspective on the clinical application of a systems stability paradigm to the differential diagnosis of ADHD and bipolar disorder  I. Szpindel, Canada		
		P-21-004	Predictors of reading speed among a sample of Turkish patients with ADHD
P-20-010	Similarity of subjective symptoms in persons with ADHD and Asperger's disorder T. Tokumasu, Japan T. Motira, S. Nobuyuki, D. Ikuse, G. Arai, Y. Okajima, A. Iwanami		and dyslexia: A preliminary study Z. Topal, Turkey E. Tufan, N. Demir, M. A. Cansiz, U. Savci, S. Taskiran, E. Demirbas Cakir, H. Harmanci, B. Semerci
P-20-011	High-dimensional pattern classification in never-treated adults with Attention- Deficit/Hyperactivity Disorder using mor- phometric and DTI data T. Avancini, Brazil	P-21-005	Longitudinal effect of Attention-Deficit/ Hyperactivity Disorder symptoms on de- pression and aggression M. Tsujii, Japan H. Ito
P-20-012	M. A. Silva, J. Doshi, M. Zanetti, M. Serpa, M. Louzã, C. Davatzikos, G. Busatto	P-21-006	Relationship between academic achieve- ment and developmental disabilities among Japanese elementary and junior high school children A. Uemiya, Japan H. Ito, Y. Murayama, M. Katagiri, M. Hamada, M. Tujii
	Evidence for adult Attention-Deficit/Hyper- activity Disorder (aADHD) as a neuro- psychological and not a cognitive disorder W. Human, South Africa A. Burke		
	, a barne	P-21-008	About variability of comorbidity in ADHD:
P-21	Guided Poster Tour		New findings of comorbidity in a clinically referred sample of children and adoles-
16:00-17:30			cents with Attention-Deficit/Hyperactivity Disorder in Switzerland A. M. Werling, Switzerland S. Walitza
Co-morbidit Chair:	y disorders – children and adolescents II E. Taylor, United Kingdom		
P-21-001	Comorbidity and correlates of disruptive mood dysregulation disorder in 6 to 8 year-old children with ADHD E. Schilpzand, Australia P. Hazell, J. Nicholson, V. Anderson, D. Efron, T. Silk, E. Sciberras, M. Mulraney	P-21-009	Comorbidity and persistent Attention- Deficit/Hyperactivity Disorder symptoms from childhood to adolescence in Brazilian sample: A four-year follow-up study S. M. Palma, Brazil A. C. Motta Palma Natale, H. M. Calil



P-22	Guided Poster Tour	P-22-010	The association between metabolic syn-
16:00 – 17:30 Co-morbidity Chair:	Hall 2 – Poster Area / disorders – Adults S. Kooij, The Netherlands		drome, obesity-related outcomes and adult Attention-Deficit/Hyperactivity Disorder D. Wynchank, The Netherlands D. Bijlenga, F. Lamers, S. Kooij, A. Bron, A. Beekman, B. Penninx
P-22-001	Suicidal behaviour in young adults with ADHD history A. L. Chirita, Romania M. C. Pirlog	P-22-011	The development of comorbid anxiety in adults with ADHD: Demographic, developmental and psychosocial risk factors and predictors
P-22-003	Sex- and subtype-related differences in the comorbidity of adult ADHD on axis I and axis II S. Gross-Lesch, Germany		J. Bramham, Ireland K. Grogan
	C. Jacob, A. Dempfle, S. Reichert, T. Jans, J. Geissler, S. Kittel-Schneider, T. Nguyen, A. Reif, KP. Lesch	P-23	Guided Poster Tour
		16:00-17:30	Hall 2 – Poster Area
P-22-004	Adult ADHD and comorbid somatic disease. A literature review J. Instanes, Norway J. Haavik	Pathophysio Chair:	logy – Children and adolescents S. Cortese, Italy
		P-23-002	Psychopathology, executive functioning and functional impairment between referred vs. non-referred ADHD adolescents
P-22-005	Depression and anxiety influence the Wisconsin card sorting test of elderly with and without Attention-Deficit/ Hyperactivity Disorder (ADHD): Preliminary results M. Klein, Brazil A. K. Menezes, T. M. Alves, M. R. Louzã		siblings L. Palacios-Cruz, Mexico A. Arias-Caballero, C. Benjet, P. Mayer, C. Cruz Fuentes, R. E. Ulloa, N. González Reyna, A. Fragoso, P. Clark, M. d. Carmen Lara Muñoz, J. C. Pérez Castro, F. de la Peña, A. Sepúlveda-Sastré
P-22-006	ADHD comorbidity and related factors in adults with generalized anxiety and obsessive compulsive disorders: A preliminary study E. Ozten, Turkey E. Tufan, G. Hizli Sayar, G. Eryilmaz, O. Karamustafalioglu	P-23-003 P-23-004	Sensory processing difficulties in special education needs (SEN) school children—a preliminary survey S. Perera, United Kingdom J. Kaleyias, A. Abdussalam Emotional dysregulation of ADHD in
P-22-007	Are wandering minds and swinging moods linked to depression in adults with ADHD?  C. Ryckaert, United Kingdom  C. Skirrow, F. Rijsdijk, J. Kuntsi, P. Asherson		childhood predicts maintenance of hyperactive-impulsive symptoms in early adulthood Q. Qian, People's Republic of China W. Chang, X. He, L. Yang, L. Liu, Q. Ma,
P-22-008	Comorbid symptoms in adults with ADHD N. Saga, Japan T. Motira, T. Tokumasu, D. Ikuse, G. Arai, Y. Okajima, A. Iwanami	P-23-005	Y. Li, L. Sun, Q. Qian, Y. Wang  Are ADHD children efficient foragers?  Evidence from the ecologically based ball- search field task
P-22-009	Adult ADHD and personality disorders: A Spanish sample J. Sevilla, Spain I. Basurte, L. Serrano, A. Sedano, R. Navarro		M. Rosetti, Mexico R. E. Ulloa, E. Reyes-Zamorano, L. Palacios- Cruz, F. de la Peña, R. Hudson

P-23-006	Presentation modality influences phono-	P-24	Guided Poster Tour
	logical working memory performance in children with ADHD: The impact of audi- tory, visual, and combined modalities D. E. Sarver, USA M. J. Kofler, E. Wells	16:00 – 17:30 Neuroimagii Chair:	n <mark>g II</mark> U. Müller, United Kingdom
P-23-008	The influence of high trait anxiety on attentional lapses in drug-naïve children with ADHD L. Sorensen, Norway	P-24-001	A meta-analysis of fMRI studies in disrup- tive behavior disorder J. Radua, Spain K. Rubia, A. Alegria
	D. Wollschläger, H. Eichele, M. F. Høvik, H. v. Wageningen, M. K. Worren, S. Adolfsdottir, O. B. Fasmer, K. J. Plessen	P-24-002	Neuroimaging analysis for patients with ADHD in South Korea S. M. Bae, Republic of Korea YE. Lee, SJ. Cho, EJ. Choi, Y. D. Son
P-23-010	Long-term memory for names in ADHD children S. Kiselev, Russia	P-24-003	Multimodal investigation of the role of the iron metabolism in increased substantia nigra echogenicity in ADHD
P-23-011	Objectivity in clinical diagnosis of ADHD by means of AULA virtual reality based neuropsychological test: Initial findings U. Diaz-Orueta, Spain		J. Geissler, Germany SY. Dang, S. Schaeff, L. Schneider, C. Drepper, S. Neufang, M. Gerlach, M. Romanos
P-23-012	M. A. Fernandez Fernandez, G. Climent  Executive functions and academic performance in children with ADHD  U. Diaz-Orueta, Spain  M. V. González-Maya, I. Martínez-Álvarez,	P-24-004	Post-error behaviour in adults with ADHD is mediated by a chronically under-activated prefrontal cortex J. Hudak, Germany S. Deppermann, F. Haeussinger, A. C. Ehlis
	P. Martín-Lobo	P-24-005	Norepinephrine transporter binding and personality traits in patients with
P-23-013	Motor and perceptual-manipulative difficulties in children with ADHD in primary school education U. Diaz-Orueta, Spain M. d. Carmen Domínguez-Hildalgo, A. B. Navarro-Prados, P. Martín-Lobo		Attention-Deficit/Hyperactivity Disorder investigated with PET and (S,S)-[18F] FMeNER-D2 A. Kautzky, Austria K. Papageorgiou, H. Sigurdardottir, A. Hahn, G. Kranz, M. Spies, T. Vanicek, C. Rami-Mark, T.
P-23-014	AULA virtual reality test and EDAH observation scale: Complementary resources in the identification of ADHD U. Diaz-Orueta, Spain A. Zulueta, N. Crespo-Eguílaz		Traub-Weidinger, M. Hacker, M. Mitterhauser, W. Wadsak, S. Kasper, R. Lanzenberger
		P-24-006	Microstructural abnormalities in adolescents with ADHD: A diffusion tensor imaging study B. G. Kylyc, Turkey M. Ö. Metin, C. Kan Gürkan, D. Gökçay



P-24-007	Early cerebellar anomalies show sexual dimorphism in preschool children with ADHD M. Mahone, USA D. Crocetti, B. Dirlikov, K. Slifer, M. Denckla, S. Mostofsky	P-25-006	Delivering behavioural parent training in different cultural settings and online: New forest parenting programme M. Thompson, United Kingdom C. Laver-Bradbury, D. Daley, AM. Lange, G. Tripp, S. Shimabukuro, C. Thompson, E. Sonuga-Barke, A. Au	
P-24-008	Comparative meta-analysis of functional and structural deficits in ADHD and OCD L. Norman, United Kingdom C. Carlisi, S. Lukito, H. Hart, D. Mataix-Cols, J. Radua, K. Rubia	P-25-007	Group cognitive-behavioral therapy for adolescents with Attention-Deficit. Hyperactivity Disorder: A randomized controlled trial R. Vidal, Spain J. Castells, V. Richarte, G. Palomar, M. Garcia,	
P-25	Guided Poster Tour		L. Lazaro, M. Casas, J. A. Ramos-Quiroga	
Non-pharm	Non-pharmacological treatment—children and apy for children adolescents III Hyperactivity Chair: M. Arns, The Netherlands controlled trial P-25-001 The cognitive training with motivation for children with ADHD symptoms and		Efficacy of an integrated behavioral therapy for children with Attention-Deficit/ Hyperactivity Disorder: A randomized controlled trial L. Yang, People's Republic of China L. Shuai, M. Chen, Y. Qian, Y. Wang	
	<b>low working memory</b> K. Rzenca, Poland B. Mrozinski, G. Sedek, A. Orylska	P-26	Guided Poster Tour	
P-25-002	Educational intervention programme for children with ADHD in primary education C. Peres, Spain	Chair:	acological treatment – adults A. Philipsen, Germany	
P-25-002 P-25-003	children with ADHD in primary education	Non-pharm	acological treatment – adults	
	children with ADHD in primary education C. Peres, Spain J. Dosil Díaz, F. Cardelle Garcia  Efficacy of a collaborative school-home intervention for Attention-Deficit/Hyper-	Non-pharm Chair:	A. Philipsen, Germany  Group therapy for university students with Attention-Deficit/Hyperactivity Disorder Y. Furuhashi, Japan S. Furuhashi  Psychoeducational groups for adults with ADHD and their significant others (PEGASUS): An open clinical feasibility trial T. Hirvikoski, Sweden	
	children with ADHD in primary education C. Peres, Spain J. Dosil Díaz, F. Cardelle Garcia  Efficacy of a collaborative school-home intervention for Attention-Deficit/Hyperactivity Disorder L. Pfiffner, USA M. Rooney, L. Haack, N. Kunin, M. Capriotti, A. Beaulieu, M. Plageman, K. Delucchi,	Non-pharm Chair: P-26-001	A. Philipsen, Germany  Group therapy for university students with Attention-Deficit/Hyperactivity Disorder Y. Furuhashi, Japan S. Furuhashi  Psychoeducational groups for adults with ADHD and their significant others (PEGASUS): An open clinical feasibility trial	

P-26-004	Edinburgh pilot study of a psycho-	P-27	Guided Poster Tour	
	education programme for adults with Attention-Deficit/Hyperactivity Disorder	16:00 – 17:30 Hall 2 – Poster Area		
P-26-005	R. Jones, United Kingdom  Dialectical behaviorally inspired psychotherapy for adults ADHD: Preliminary results  N. Perroud, Switzerland  P. Prada, J. Zimmermann, JM. Aubry, R. Nicastro	Pharmacological treatment – children and adolescents III Chair: J. Halperin, USA		
		P-27-001	Predictors of relapse or maintenance of response of Attention-Deficit/Hyperactivity Disorder symptoms after discontinuation of long-term treatment with atomoxetine	
P-26-006	CBT for adult ADHD and implementation strategies: An open pilot study		J. Thome, Germany R. Escobar, S. Lipsius, H. Upadhyaya	
	R. Ramsay, USA A. Rostain	P-27-002	Stroop interference in patients with Attention-Deficit/Hyperactivity Disorder	
P-26-007	CBT for adult ADHD: An open pilot study of effects on functional status R. Ramsay, USA A. Rostain		M. Vallejo, Spain P. deCastro-Manglano, A. Diez-Suárez, A Figueroa-Quintana, J. J. Marín-Méndez, C Soutullo-Esperón	
P-26-008	The effects of a Self-Alert Training (SAT) programme in adults with ADHD S. Salomone, United Kingdom G. R. Fleming, J. M. Shanahan, M. Castorina, J. Bramham, R. G. O'Connell, I. H. Robertson	P-27-003	The effect of GXR (guanfacine) as adjunctive treatment with stimulant therapy on executive function and quality of life: A phase IV, single-centre, randomized, double-blind, placebo controlled, crossover evaluation	
P-26-009	rTMS of 1Hz helps to reduce MPH in a patient suffering from ADHD H. Niederhofer, Germany		J. van Stralen, Canada E. Corsi	
P-26-010	Cognitive behavioral therapy for adults with Attention-Deficit/Hyperactivity Disorder: Protocol of a randomized controlled trial F. Huang, People's Republic of China QJ. Qian, YF. Wang	P-27-004	Clinical response and symptomatic remission in adolescents with Attention-Deficit/ Hyperactivity Disorder receiving guanfacine extended release in a phase 3 study T. E. Wilens, United Kingdom L. Harper, J. L. Young, V. Sikirica, G. Rynkowski, B. Dirks, A. Cutler	
P-26-011	NIRS neurofeedback as a treatment method in adult Attention-Deficit/Hyper- activity Disorder B. Barth, Germany AC. Ehlis, K. Mayer, F. Häußinger, A. Fall- gatter, U. Strehl	P-27-005	Safety outcomes from a phase 4, open- label, multicentre, 2-year study of lis- dexamfetamine dimesylate in children and adolescents with Attention-Deficit/ Hyperactivity Disorder A. Zuddas, Italy T. Banaschewski, P. Nagy, C. Soutullo, B. Yan, B. Caballero, D. R. Coghill	
		P-27-006	Mirtazapine for weight loss and insomnia associated with methylphenidate: A chart review S. Herguner, Turkey A. Herguner	



P-27-007	Evaluating clinician time and clinic resource utilisation—a novel measure of lisdexamfetamine dimesylate's efficacy in children with ADHD M. Mcconkey, United Kingdom	P-28-006	Integrated ADHD clinical care pathways (ICP) can contribute to reduced patient journeys and enhance quality of care: Benefits of an ADHD ICP in a Hertfordshire child development centre (CDC)	
P-27-008	Effect of neurofeedback home training with stimulant medication on concentration compared to stimulant medication only: A single-case study in an Attention-Deficit/Hyperactivity Disorder (ADHD) population H. Wachnianin, United Kingdom P. Corr, N. Rutterford	P-28-008	I. Takon, United Kingdom S. Ozer  Sleep-efficiency in adult Attention-Deficit/ Hyperactivity Disorder using actigraphy over 5 days S. Schiebler, Switzerland L. Kuster, M. Wenke, T. Müller	
D 20	Guided Poster Tour	P-28-009	The children's attention project: 18-month outcomes from a community-based cohort of children with ADHD and non-	
P-28 16:00 – 17:30 Quality of li Chair: P-28-001		P-28-010	ADHD controls E. Sciberras, Australia J. Nicholson, V. Anderson, P. Hazell, B. Jongeling, T. Silk, M. Bisset, O. Ukoumunne, D. Efron  ADHD Club—a new Portuguese social entrepreneurship initiative F. Silva, Portugal R. Antunes, S. Afonso, C. Rosa, A. Serrão	
	Kanata, S. Fujikawa, S. Ando, M. Hasegawa, K. Kasai		Neto	
P-28-003	Factors associated with a positive occupa-	P-29	Guided Poster Tour	
	tional outcome during long-term central stimulant treatment in adult ADHD T. Torgersen, Norway A. E. Vaaler, S. Krokstad	16:00 – 17:30 Quality of li Chair:	Hall 2 – Poster Area  ife / Caregiver burden IV  O. Tucha, The Netherlands	
P-28-004	Social-emotional correlates of ADHD symptomatology in college students T. Mckee, USA J. DeVinney, C. Hobgood	P-29-001	Executive functions and pedestrian safety in children with ADHD M. Toye, United Kingdom J. Thomson, D. Coghill, S. Rhodes	
P-28-005	Clinical characteristics of adults with ADHD or ASD admitted to emergency psychiatric wards in Japan T. Morita, Japan A. Iwanami, H. Yamada, D. Ikuse, T. Tokumasu, N. Saga, G. Arai	P-29-002	Driving performance of adults with Attention-Deficit/Hyperactivity Disorder L. Tucha, The Netherlands A. B. M. Fuermaier, J. Koerts, S. Aschenbrenner, K. Brookhuis, B. Lewis-Evans, D. de Waard, K. W. Lange, O. Tucha	

P-29-003	The development and implementation of a point-of-referral educational tool to enhance knowledge transfer about Attention-Deficit/Hyperactivity Disorder J. van Stralen, Canada	P-29-011	Association between parenting style and socio-emotional and academic functioning in children with and without ADHD: A community-based study S. Bhide, Australia E. Sciberras, V. Anderson, J. Nicholson
P-29-004	Audit on ADHD guidelines for adults from transition to maintenance	D 20	
	R. Ijaz-Ul-Haq, United Kingdom A. Delgado-Hernandez	P-30	Guided Poster Tour
P-29-005	Sibling of children with Attention-Deficit	16:00 – 17:30 Substance al	
. 15 003	Hyperactivity Disorder's knowledge and perception on core symptoms and their	Chair:	G. van de Glind, The Netherlands
	role in clinical intervention C. Viana, Portugal C. Chasqueira, R. Lopes, P. Cabral, R. Carmona	P-30-001	ADHD in the context of clients initiating treatment in therapeutic communities in the Czech Republic  L. Cablova, Czech Republic
P-29-006	Experiences of adolescents and young adults with ADHD in Hong Kong: Treat-		M. Miovsky, L. Stastna, K. Kalina
	ment services and clinical management I. Wong, People's Republic of China K. Cheung, P. Ip, P. Chan, C. Lin, L. Wong, E. Chan  Mothers' involvement in assisting with homework in relation to children's ADHD symptoms and mothers' self-efficacy be-	P-30-002	Risk of abuse of tobacco, alcohol and illegal drugs in a Spanish sample of young adults with ADHD: Relationship with manifestations of comorbid problems C. Colomer, Spain A. Miranda, R. Roselló, C. Berenguer, B. Roselló
P-29-007			
	<b>liefs</b> M. Wozniak-Prus, Poland M. Gambin, M. Florczak-Perchel, M. Swiecicka		International rates of ADHD and substance use disorder symptoms among prison inmates: Individual data and pooled effects R. Gonzalez, Puerto Rico
P-29-008	Contemporary challenges faced by Canadian physicians in ADHD management J. F. Yaremko, Canada D. T. Duncan, S. SK Kao, R. Kronfli		M. Velez-Pastrana, G. Gudjonsson, Y. Ginsberg, M. Konstenius, A. Alicea, C. Albizu, S. Young
P-29-009	Academic outcomes for young people with ADHD transitioning to secondary school: The moving up study N. Zendarski, Australia E. Sciberras, F. Mensah, H. Hiscock	P-30-004	Retrospective observational study on the effect of specific psychopharmacological treatment of ADHD in childhood related to the presence of substance use disorder in adulthood L. Llopart, Spain
P-29-010	Prospective study on cognitive function, academic, performance and tolerability of OROS-methylphenidate in children with Attention-Deficit/Hyperactivity Disorder Y. Zheng, People's Republic of China JM. Liang, Hy. Gao		G. Español, V. Valles, e. Jovell, B. Pineiro- Dieguez



P-30-005	Attention-Deficit/Hyperactivity Disorder among stable heroin dependent patients in opioid substitution treatment J. Martinez-Raga, Spain M. Miñano Meneres, J. Cebrián Gallardo, N. Garcia Sanchez, J. Vivas Lalinde, F. Andrés	P-31-004	Child maltreatment and associated parental factors among children with ADHD: A comparative study C. K. Gurkan, Turkey H. Gül, C. K. Gurkan Partial agenesis of corpus callosum (ACC)
	España, G. Legazpe García, A. Lopez de Haedo, M. Herrero Casanova, R. Calabuig Crespo, A. Torregrosa Vales  Is Alcohol, Smoking and Substance Involvement Screening Test (ASSIST) a good screening instrument for patients with Attention-Deficit/Hyperactivity Disorder (ADHD)?	1-31-003	in adult Attention-Deficit/Hyperactivity Disorder (ADHD) W. Jaimes-Albornoz, Spain
P-30-006		P-31-006	A. Ballesteros-Prado  Telepsychiatry experience in managing complex ADHD cases in northern Ontario: An integrated service delivery model
	C. S. Miguel, Brazil M. A. Silva, T. Chaim-Avancini, M. R. Louzã		R. Jain, Canada T. Pignatiello, D. Willis
P-30-007	Correlates of everyday executive functioning in ADHD and substance abuse	P-32	Guided Poster Tour
	R. Roselló, Spain	16:00-17:30	Hall 2 – Poster Area
	A. Miranda, C. Colomer, C. Berenguer, J. Mercader	Míscellaneo Chair:	us II P. Riederer, Germany
P-30-008	Long-term outcomes of pharmacologically treated versus non-treated adults with ADHD and substance use disorder: A naturalistic study B. Bihlar Muld, Sweden J. Jokinen, S. Bölte, T. Hirvikoski	P-32-001	Review: Transcultural approach on ADHD: From cultural differences to different so- cials answers B. Gonzales, France C. Verna, M. Larson, P. Gerardin, AS. Martin
		P-32-002	PISTTA project: A telematic longitudinal
P-31	Guided Poster Tour		study of ADHD in Spain I. Onandia, Spain
16:00-17:30			Z. Garcia
Míscellaneo Chair:	us I Caterina Gawrilow, Germany	P-32-004	Validity of the computer-based cognitive tasks for schoolaged children: Memory
P-31-001	Relationship between emotional intelligence and self-concept in ADHD U. Diaz-Orueta, Spain		and working memory tasks MS. Shin, Republic of Korea S. J. Oh, J. J. Lee
P-31-002	I. Pérez-Tamargo, D. Ribes, P. Martín-Lobo  Knowledge about Attention-Deficit/ Hyperactivity Disorder among teachers G. Gaastra, The Netherlands Y. Groen, A. Fuermaier, L. Tucha, O. Tucha	P-32-005	Development of the computerized test to diagnose dyscalculia in Korean children and adolescents C. Suh, Republic of Korea H. Yoo, Y. Y. Kim, J. Jung
P-31-003	Ethical relevant issues concerning ADHD. Opinions of psychiatrists, pharmacists and medical practitioners: Does background matter? W. Göttgens-Jansen, The Netherlands E. van Leeuwen	P-32-006	'The feeling distracts me and I forget the question' – a qualitative study of premonitory urges in children with tic disorders I. Takon, United Kingdom H. Rickards, U. Chowdhury, S. Sharma

Saturday, 30 May 2015

P-32-007 Knowledge and beliefs of parents, teach-

ers and mental health professionals in

Mexico about ADHD

E. Ulloa, Mexico

L. Palacios, F. De la Peña, G. Victoria, A. Novelo

P-32-008 Development of the comprehensive learn-

ing test-reading for the Korean children

and adolescents

H. Yoo, Republic of Korea

J. Jung, I. Choi

ES-5 Educational Seminar

Paying attention in meta-analyses: Learning to read them through recent meta-analyses in ADHD

ES-5-001 Paying attention in meta-analysis: Learing

to read them through recent meta-analysis in ADHD

C. Maia, Brazil

S. Cortese, Italy

ES-6 Educational Seminar

Non-pharmacologic treatment of ADHD and OCD in children and adolescents

ES-6-001 Non-pharmacologic treatment of ADHD

and OCD in children and adolescents

J. Geissler, Germany

ES-7 Educational Seminars

Oppositional defiant disorder and ADHD

ES-7-001 Oppositional defiant disorder and ADHD

D. Quinn, Canada

ES-8 Educational Seminar

Optimizing medication management of adult ADHD

ES-8-001 Optimizing medication management of

adult ADHD P. Mattos, USA

C.B. Surman, USA

ME-5 Meet-the-Expert Session

Neurobiology of ADHD

ME-5-001 Neurobiology of ADHD

F. X. Castellanos, USA

ME-6 Meet-the-Expert Session

Treatment of adult ADHD

ME-6-001 Treatment of adult ADHD

M. Weiss, Canada

ME-7 Meet-the-Expert Session

New ways of understanding ADHD neuropsychology and how they might inform clinical practice

ME-7-001 New ways of understanding ADHD neu-

ropsychology and how they might inform

clinical practice

E. J. S. Sonuga-Barke, United Kingdom



Sunday, 31 May 2015

PL-4 Plenary Session

08:30 – 10:30 Clyde Auditorium

Controversies in ADHD

Chairs: E. Taylor, United Kingdom

P. Riederer, Germany

PL-4-001 Are we facing a worldwide ADHD epi-

demic?

E. Taylor, United Kingdom

PL-4-002 Do prenatal environmental factors con-

tribute to the risk for ADHD?

D. Coghill, United Kingdom

PL-4-003 Is ADHD only a neurodevelopmental dis-

order?

G. Polanczyk, Brazil

PL-4-004 Should available pharmacogenetic tests

be used to inform clinicians on deciding

**about treatment?** M. Bellgrove, Australia

10:30 – 11:00 Break

PL-5 Plenary Session

11:00 – 13:00 Clyde Auditorium

New advances in the treatment of ADHD

Chairs: D. Coghill, United Kingdom

J. Thome, Germany

PL-5-001 Beyond stimulants and behaviour modi-

fication: New directions for treatment development in ADHD: The next 20 years

J. Halperin, USA

PL-5-002 Cognitive behaviour therapy interventions

for adults with ADHD

M. Solanto, USA

PL-5-003 What future research should bring to help

resolving the debate about the efficacy of EEG-neurofeedback in children with

ADHD?

J. Buitelaar, The Netherlands

PL-5-004 The potential role of transcranial magnetic

stimulation in the treatment of ADHD

R. Zaman, United Kingdom

**Closing Ceremony** 

13:00 – 13:30 Clyde Auditorium

▶ Congress summary

▶ Presentation of best poster awards

▶ Announcement of the

6<sup>th</sup> ADHD World Congress 2017

## **EDUCATIONAL GOALS**

Friday, 29 May 2015

ES-1 **Educational Seminar** 

17:00 - 18:00 Carron 1/2

Organisation and carrying out of parent training in **ADHD** 

Chair: C. Neuhaus, Germany

Purpose of the seminar: Improving the communicationstrategies in families with ADHD.

Description of the seminar content: Children with ADHD have at least one parent, who has ADHD as well (and knows the effect of negative communication: one fails to react as one wants or should do). Parents should be exceptionally well versed in the functionality of the brain with ADHD, as those with one, are, amongst other things. at the mercy of their emotions. This level of understanding requires the assistance of a therapist with profound knowledge of ADHD in childhood, during adolescence as well as in adulthood with all it's comorbidities. If parents really understand this specific dysregulation of emotion, motivation and self-discipline, they can develop a positive attitude towards the unique style of perception and reaction in the family, learn to talk without nagging, to react supportively, and to announce every task in a friendly fashion (incl. learning to analyze conflicts and coping with selfmanagement deficits). If it is understood that the child does not want to react inadequately and suffers from its faults (along with the parent!) and parents are prepared that "surprises" may happen every minute of the day, they can react promptly, albeit relaxed, and able to immediately reinforce the next positive behavior. Since punishment or negative consequences worsen the family interaction and childs self-esteem, as has been proven in clinical practice, the neuro-biological understanding of the child with ADHD is essential to shift these into the positive.

Audience to be addressed: Healthcare professionals interested in getting an overview in ADHD-specific parent training.

ES-2 **Educational Seminar** 

17:00-18:00

Alsh 1/2

Ambulatory assessment to study ADHD patients in their natural environment

Chair: C. Gawrilow, Germany F. Schmiedek, Germany

**Objectives:** Ambulatory assessment and experience sampling methods have important advantages for behavioral science. First, objective measures of behavior and subjective experience collected in real life provide more ecologically valid information than assessments in the laboratory or retrospective self-reports. Second, measuring persons repeatedly over many occasions provides the necessary data to investigate intraindividual variability and withinperson processes. Given the importance of behavioral variability in ADHD and its multifaceted symptomatology, these aspects carry particular promise for research on this disorder. Here, fluctuations of cognitive performance at different timescale levels (moment-to-moment, within and across days) and potential antecendent factors (e.g., mood and motivation) will be used as an example to show how multilevel models for repeated measures can be applied to analyze ambulatory assessment data and address research questions of (a) whether certain variables exhibit systematic fluctuations within persons, (b) whether and how such fluctuations are coupled across different variables, and (c) whether and how persons differ in the strength of these couplings.

Data from 110 third and fourth graders (without diagnosis of ADHD) who took part in an ambulatory assessment study over four weeks are used to illustrate the application of multilevel models. On each day, children did several trials of two working memory updating tasks (numerical and spatial) on smartphones and provided self-reports (e.g., affect, motivation, sleep) on up to four occasions each day during school and leisure time. Working memory performance reliably fluctuated across and within days. Fluctuations were significantly associated with other variables, like sleep, affect, and motivation. Children differed in the amount of fluctuations and in the strength of couplings to other variables. Multilevel models allow investigating within-person processes and between-person differences therein and are therefore perfectly suited to analyze data from ambulatory assessment studies. Extensions and alternatives (like multilevel structural equation or time series models) are discussed. Another study extends this work by addressing the question of whether ADHD symptoms show considerable daily fluctuations within-person, and analysing the factor structure of such symptom fluctuations. Altogether, 255 adolescents with and without



## **EDUCATIONAL GOALS**

Friday, 29 May 2015

ADHD rated their daily inattentiveness, hyperactivity, and impulsivity (Conners, 2008; Döpfner, Görtz-Dorten, Lehmkuhl, Breuer, & Goletz, 2008) on eight consecutive days. By means of intra-class correlation coefficients and multilevel confirmatory factor analyses we analyzed symptom fluctuations and symptom factor structure both on the trait-like between-person level (i.e., averaged across days) and on the within-person level.

The results replicate previous findings supporting both unity and diversity among symptoms on a trait-like between-person level with the superior fit of hierarchical models. The unique contribution of our study is that we demonstrate substantial within-person symptom fluctuations that are represented best by a within-person factor structure resembling the hierarchical between-person factor structure. Practical and theoretical implications of the ambulatory assessment of ADHD symptoms (inattention, hyperactivity, impulsivity) and its correlates as for instance cognitive functions, motivation, and activity will be discussed, taking into account possible influences of daily environmental variations.

ES-3 Educational Seminar

17.00-18.00 h

O Clyde Auditorium

New assessment strategies of ADHD in adults

Chairs: A. Philipsen, Germany W. Retz, Germany

The diagnosis of Attention-Deficit/Hyperactivity Disorder (ADHD) in adults is a complex process especially if the disorder was not diagnosed during childhood. Different databases and data sources have to be considered. The seminar provides an overview of general problems of the assessment, the different steps of the diagnostic process and the instruments which can be useful to diagnose adult ADHD. Available are interviews, self and observer rating scales. Finally some unsolved issues in the assessment of ADHD in adults are discussed.

ES-4 Educational Seminar

17.00-18.00 h

Lomund Auditorium

To treat or not to treat - controversies and difficulties related to treatment of this population – psychosocial treatment, what do we know?

Chairs: J. A. Ramos-Quiroga, Spain G. van de Glind, The Netherlands

**Purpose of the seminar:** To review the management of ADHD with SUD.

Description of the seminar content: During the last forty years there has been an increasing level of evidence that ADHD affects adults. The prevalence of ADHD in adults is significantly higher within clinical samples compared to the results obtained from studies within the general population. The prevalence of ADHD in adults is significantly higher within clinical samples compared to the results obtained from studies within the general population. In the first multinational study on the prevalence of ADHD in treatment-seeking SUD adult patients, based on the DSM-IV criteria, adult ADHD varied between countries, from 5.4% (95% CI: 2.4-8.3) in Hungary to 31.3 % (95% CI: 25.2-37.5) in Norway. The new version, DSM-5, makes more explicit references to the progression of ADHD into adulthood, adapting the current criteria to the disorder's evolutionary reality. In order to assess the comorbidity of ADHD in adults there are useful interviews, including the Psychiatric Research Interview for Substance and Mental Disorders IV (PRISM-IV) and the Mini International Neuropsychiatric Interview-Plus (MINI-Plus). The drugs indicated for the treatment of ADHD in adults are the same to those recommended for children and adolescents. There have been many more clinical trials evaluating the efficacy and safety of the drugs used in ADHD treatment on children than adults. It is important to highlight the positive impact of ADHD treatment for adults in terms of improving aspects of their daily functioning.

Audience to be addressed: Clinicians and biologists

## **EDUCATIONAL GOALS**

Saturday, 30 May 2015

ES-5

**Educational Seminar** 

17.00-18.00 h

Carron 1/2

Paying attention in meta-analyses: Learning to read them through recent meta-analyses in ADHD

Chairs: C. Maia, Brazil S. Cortese, Italy

**Purpose of the seminar:** To provide attendees a methodological guidance on the understanding, interpretation and critical appraisal of recent relevant meta-analyses on ADHD.

**Description of the seminar content:** With reference to recent meta-analyses on the pharmacological and non-pharmacological treatment of ADHD, as well as on its neurobiological correlates, Through our recent published meta-analysis of pharmacological and non-pharmacological treatments for ADHD, and a meta-analysis on ADHD prevalence, we will discuss: 1) adequacy of the research question(s); 2) how to evaluate the methodology; 3) how to read and interpret the results, tables and graphs; 4) clinical implications of results.

**Audience to be addressed:** Mental health professionals/ clinicians searching for evidence-based material for clinical practice, and junior researchers who wish to acquire expertise in conducting meta-analyses.

ES-6

**Educational Seminar** 

17.00-18.00 h

O Alsh 1/2

Non-pharmacologic treatment of ADHD in children and adolescents

Chair: J. Geissler, Germany

Objectives: This seminar aims at providing an overview of the evidence-basis of current non-pharmacological interventions for ADHD. State-of the art treatment of childhood and adult ADHD in the literature comprises in addition to psychostimulant medication a wide variety of non-pharmacological options. Available non-pharmacological interventions range from cognitive training and dietary modifications to physiological approaches like neurofeedback or transcranial directcurrent stimulation and behavioural interventions such as cognitive-behavioural therapy, intensive summer treatment programs or parent trainings. In the first part of the seminar, the focus will be on cognitive-behavioural interventions targeting social skills, organization and planning and emotion regulation for children and adults. In the second part, neurobiological interventions will be introduced, with a specific focus on neurofeedback as a computer-based method for improving self-regulation of vigilance and other basic brain states. We will furthermore discuss predictors of treatment outcome that may be useful in the clinical setting for informing individual treatment decisions as well as recommendations to patients and caregivers depending on factors such as psychiatric comorbidities and the needs of adults with a diagnosis of ADHD. Clinical practicioners, researchers, patients with adult ADHD and caregivers of children with ADHD.

**ES-7** 

**Educational Seminar** 

17.00-18.00 h

Forth room

Oppositional defiant disorder and ADHD

Chair: D. Quinn, Canada

**Objectives:** ODD has become a renewed focus of research and there has been a sub-classification of ODD in the DSM -5 in 2015 to three potential subtypes, Irritable, Headstrong and Vindictive. The sub-classification of ODD is questionable. The clinical presentation of ODD can be confused with Disruptive Mood Dysregulation Disorder (DMDD) and Intermittent Explosive Disorder (IED) and Bipolar Disorder. This seminar will cover these issues, and discuss whether ODD is inherently a disorder of Irritability and should perhaps be renamed a disorder of Emotional Regulation. The impact of ODD in the clinical outcome of ADHD has been under recognized and poorly understood and will be reviewed.

ES-8

**Educational Seminar** 

17.00-18.00 h

O Lomund Auditorium

Optimizing medication management of adult ADHD

Chairs: P. Mattos, USA C. B. Surman, USA

Objectives: Judicious prescribing is a prerequisite for appropriate treatment of ADHD and proper clinical evaluation of the adult with a possible ADHD diagnosis is the first step. Inattention can be secondary to a myriad of different problems, to begin with. To complicate further, many disorders, which comprise inattention as part of their symptomatology, can often occur in comorbidity with ADHD. In addition, some comorbid disorders should be considered as potential limitations for ADHD treatment, even if they often co-occur, like epilepsy. This presentation will guide the audience to choose between existing medications to personalize treatment of adult ADHD. While there are few studies that directly compare agents, experience treating adults with ADHD over the last decade suggests that treatment can be optimized based on an understanding of key factors. These factors include mechanism of action, duration of action, utility in comorbid conditions, pattern of effects on traits associated with ADHD, and contraindications due to medical conditions or interaction with other medications.



#### **CONGRESS VENUE**

Scottish Exhibition and Conference Centre SECC Exhibition Way
Glasgow G3 8YW, United Kingdom

#### **CONGRESS REGISTRATION COUNTER**

All congress materials and documentation will be available from the congress registration counter located in hall 1, Scottish Exhibition and Conference Centre.

Opening Hours	
Thursday, 28 May 2015	12:00-19:30
Friday, 29 May 2015	07:30-18:00
Saturday, 30 May 2015	08:00-18:00
Sunday, 31 May 2015	08:00-13:30

During these opening hours the congress counter can be reached at: +44 - 141 - 357 34 25

Please, expect a possible waiting time of up to 45 minutes when picking up your badge on Thursday.

The congress counter will be divided into the following sections:

#### On-site registration

On-site registration for the congress.

#### Pre-registration paid

Participants who have already registered and paid for the congress will receive their documents here.

#### Pre-registration unpaid

Participants who have already registered for the congress, but have not paid yet, will receive their documents here.

Membership: Your World Federation membership fee can be paid at the on-site registration and the pre-registration unpaid counter, too.

### Glasgow information

Our Glasgow and Scotland experts will help you to enhance your experience of both the city and the rest of Scotland. The information counter is located in the registration area.

#### **REGISTRATION FEES**

Registration and Payment	from 2 April 2015
Non-member from Countries A <sup>1</sup>	EUR 500
Non-member from Countries B <sup>1</sup>	EUR 400
Member World Federation of ADHD from Countries A <sup>1</sup>	EUR 450
Member World Federation of ADHD from Countries B <sup>1</sup>	EUR 350
Students and persons under 35 years*	EUR 350
Educational Seminars**	EUR 30
Meet-the-expert Sessions**	EUR 30

<sup>&</sup>lt;sup>1)</sup> For list of countries A and B, please check the congress website.

Cash payment on site is only accepted in EUR. You can also pay by credit card.

#### Registration fee for the participants includes:

- Admission to all scientific sessions
- Admission to poster and technical exhibition
- Conference materials (delegate bag, final programme, abstract book, etc.)
- Admission to the Opening Ceremony and Networking Reception on Thursday, 28 May 2015
- Coffee breaks from Thursday to Sunday and lunches on Friday and Saturday

#### On-site registration

On-site registration will be processed on a first-come, first-served basis. Priority will be given to pre-registered delegates. Depending on the number of on-site registered delegates, availability of congress bags may be limited.

### **CERTIFICATE OF ATTENDANCE**

Please hand in your evaluation form at the counter for a certificate of attendance.

A copy of the passport and student identity card is necessary.

<sup>\*\*</sup>Only valid in combination with the congress registration fee.

#### NAME BADGES

All participants are requested to wear their name badge at all times during the congress. The colours of the name badges have the following significance:

Delegate: blue
Delegate incl. Educational Seminar/
Meet-the-expert Session: blue/yellow
Exhibitor: green
Staff: red

#### **CONGRESS LANGUAGE**

The congress language is English. Simultaneous translations will not be provided.

#### **EACCME – CONTINUING MEDICAL EDUCATION**

The 5<sup>th</sup> World Congress on ADHD is accredited by the European Accreditation Council for Continuing Education in Brussels (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS), www.uems.net.

The 5<sup>th</sup> World Congress on ADHD is designated for maximum 18 CME credit points of European external CME credits. Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Please hand in the evaluation form enclosed in the congress bag to receive a printed copy of the accreditation certificate.

Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits<sup>TM</sup>. Information on the process to convert EACCME credit to AMA credit can be found at www.ama-assn.org/go/internationalcme.

Live educational activities, occurring outside of Canada, recognized by the UEMS-EACCME for ECMEC credits are deemed to be Accredited Group.

Learning Activities (Section 1) as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada.

#### PUBLICATIONS FOR PROCEEDINGS

The organizer of the congress retains the right to publish all material presented at the congress in any congress publication.

#### INTERNET DIGITAL SERVICE AREA

Internet terminals are available to all delegates in the exhibition area in hall 2. The Internet Digital Service Area is accessible during the opening hours of the exhibition. All questions regarding digital service will be answered by staff members. The Internet Digital Service Area is supported by Shire.

## CONGRESS INFORMATION SYSTEM CO CONGRESS ONLINE®

#### www.adhd-congress.org

Participants can benefit from the web-based ADHD Congress Information System CO CONGRESS ONLINE®.

The ADHD Congress Information System provides information on:

- Updated scientific programme
- Programme by day
- Programme by formats with accepted abstracts of chairpersons and speakers
- Programme search
- List of participants (who is who)
- List of exhibitors
- ▶ General congress information
- ▶ Private mail box
- ▶ Acknowledgements of sponsors
- ▶ City of Glasgow
- ▶ Hotel accommodation
- Travel to Glasgow
- News

#### WLAN/Wi-Fi

Free access is available in hall 2. The network name is: adhd2015 The password is: adhd2015



#### **CONGRESS APP**

Get the 5<sup>th</sup> World Congress on ADHD APP for your smart phone now and experience the congress at your fingertips! Quickly find your way through the most up-to-date congress schedule. Stop carrying around piles of paper. Just take the congress with you, wherever and whenever you want! The APP is completely free and provides iPhone/iPad and Android smartphones users at the 5<sup>th</sup> World Congress on ADHD 2015 in Glasgow.





The ADHD 2015 APP is powered by GLOBIT's acclaimed CONGRESS MOBILE® software.

Further information is given at

www.adhd-congress.org/app/mobile



### TECHNICAL EXHIBITION

The 5<sup>th</sup> World Congress on ADHD will be accompanied by an exhibition in hall 2.

Opening Hours	
Thursday, 28 May 2015	15:00-21:30
Friday, 29 May 2015	09:00-17:30
Saturday, 30 May 2015	09:00-17:30
Sunday, 31 May 2015	09:00-13:00

#### POSTER EXHIBITION

The poster exhibition of the 5<sup>th</sup> World Congress on ADHD is located in hall 2 close to the technical exhibition. Posters are allocated to 32 guided poster tours (P-01 to P-32). They will be sorted by topic and will be numbered corresponding to topics. The poster exhibition is open to all participants according to the opening time of the technical exhibition:

### Guided poster tours will take place:

 The guided posters tours will be chaired by renowned specialists. Interested participants can meet the poster authors for discussion during the time of the poster tour.

### Set up times for posters

Thursday, 28 May 2015 15:00 – 19:00 Dismantling: 31 May 2015 11:00 – 13:00

Posters which have not been removed within the indicated time schedule will be removed. The poster size is 120 cm high and 90 cm wide (portrait format).

#### **AWARDS**

Scientists have been encouraged to hand in their abstracts and apply for the following award:

#### Young Scientists' Awards

Young scientists' Sessions aim at encouraging young scientists to attend this interdisciplinary congress in the field of ADHD. The sessions will be composed of 20-minute lectures. Eight young scientists' abstracts have been chosen by the Scientific Programme Committee out of 200 applications for two sessions à four presenters on Thursday, 28 May 2015. The sessions will be chaired by recognized experts. Speakers are requested to show via copy of their ID that they are younger than 40 years of age. The winners will receive a young scientist award of EUR 300 each.

#### Poster Awards

All posters will be evaluated on site and the best of each poster tour will be displayed on separate poster walls after the tour. On Sunday, 31 May 2015, the best six posters will be selected out of all poster tours by the Poster Prize Committee. Those posters will be awarded with a poster prize of EUR 500 each. The award ceremony will take place on the last congress day. Members of the Poster Prize Committee are: A. Kutzelnigg, Austria; U. Müller, United Kingdom; T. Renner, Germany; G. Polanczyk, Brazil; L. Viola, Italy

#### SPEAKERS CENTRE

The speaker's centre is located 1st floor at the seminar suite. Speakers are asked to hand in their CD ROM or USB stick, containing the PowerPoint presentation (IBM format or compatible, no multisession), preferably one day before their presentation but at the latest 90 minutes prior to the presentation. The presentation will be transferred to the central congress server and will be available afterwards on a special congress notebook in the hall of the presentation.

Due to time and technical reasons we kindly ask the speakers not to use their own notebook. Several PC working stations are provided in the speaker's centre where speakers can also work on their charts in a quiet area. Technical staff will be glad to assist.

operated by Estensis GmbH the Conference Company



Opening Hours	
Thursday, 28 May 2015	12:00-19:00
Friday, 29 May 2015	07:30-17:00
Saturday, 30 May 2015	08:00-17:00
Sunday, 31 May 2015	08:00-12:00

#### **RESTAURANTS**

Some restaurants and bars are within walking distance to the congress venue and the Clydebuilt bar/restaurant can be found at the concourse ground floor East entrance. The colleagues of the Glasgow information centre will be happy to recommend locations for dining out.

### COFFEE BREAKS AND LUNCH

Coffee and tea are served during the morning and afternoon coffee breaks from Thursday afternoon, 28 May to Sunday 31 May 2015 free of charge to all registered participants. A healthy lunch will be served in the exhibition area in hall 2 on Friday and Saturday to all registered delegates.

#### **CLOAKROOM**

A cloakroom is available on the concourse ground floor. You can also store your luggage there. Cloakroom fee per item: 2 £

#### **BANK**

An ATM machine is located in the east entrance concourse.

#### **CURRENCY**

The official currency is the pound sterling GBP (£). Exchange of foreign currency is available at Glasgow airport and in most hotels, banks and exchange offices throughout the city.

#### **ELECTRICITY**

Scotland uses a 240 volt 50 Hz system. Sockets have the Commonwealth standard and plugs are three-prong grounded.

#### LOST AND FOUND

A lost and found service is available at the registration counter of the congress.

#### **MOBILE PHONES**

Participants are kindly requested to keep their mobile phones turned off while attending the scientific sessions in the meeting rooms.

#### PROGRAMME CHANGES

The organizers cannot assume liability for any changes in the congress programme due to external or unforeseen circumstances. In the event of cancellation by speakers or other changes in the main programme, no full or partial refund of the registration fee can be made.

#### **CLIMATE**

Every cloud has a silver lining...

As the old Scottish saying goes, "there's no such thing as bad weather, only the wrong clothes!" Glasgow's high latitude means a moderate mostly warm climate with temperature between 15°C (50°F) and 20°C (61°F) in May. Light showers can occur daily this time of the season.

#### **PRESS**

Journalists should bring their press ID and register at the registration counter.

#### **INSURANCE**

The congress fee does not include insurance. All participants should arrange for their own insurance. Health and accident insurance is recommended and has to be purchased in your country of origin.



#### **REGISTRATION CONDITIONS**

The general terms for the congress registration including payment and cancellation of the World Congress on ADHD are published on the congress website:

www.adhd-congress.org

#### OFFICIAL ITALIAN AGENCY

AIM GROUP – AIM Education s.r.l. Via G. Ripamonti, 129 20141 Milan, Italy Phone:+39-02-56601 259

AIM Group is the official Italian agency which is authorised to deal with Italian Health Authorities.

# HOW TO GET FROM THE AIRPORT TO THE CONGRESS VENUE (Scottish Exhibition and Conference Centre)

The greater area of Glasgow has three airports: Glasgow International Airport, 8 miles from the city centre of Glasgow, Glasgow Prestwick Airport, 50 minutes by direct train to Glasgow city centre and Edinburg International Airport, 45 minutes by coach transfer.

#### From Glasgow International Airport:

More than 100 world-wide destinations are linked to Glasgow International Airport incl. nonstop services from Dubai, New York and Philadelphia. Regular coach shuttles are connecting the airport with the city centre. Duration depending on traffic 20–30 minutes. Taxis are available at the airport, taxi fare approx. £ 25–35 per way.

### From Glasgow Prestwick Airport:

Prestwick airport is mainly used by "no frill" airlines and connected by regular rail link to Glasgow city centre. Travel duration: 50 minutes.

#### From Edinburgh International Airport:

The Edinburgh airport is well connected to all major European hubs. A regular coach shuttle service is running every 30 minutes between Edinburgh airport and Glasgow city centre, duration 60 minutes, distance 50 km.

While planning your travel arrangements benefit from attractive airfares of our official travel partner Skyteam and its belonging airline partners. Please visit for further details our website www.adhd-congress.org.



#### **PUBLIC TRANSPORTATION**

The Exhibition Centre station is the SECC's own dedicated railway station allowing easy access from the city centre and the suburbs. Six trains per hour (around every 10 minutes) from Central station (Platform 17 is on the lower level) will bring you to Exhibition Centre station in a journey time of just three minutes. The 100 Riversider bus service runs from George Square (north) in Glasgow city centre to the SECC, then Riverside Museum and return, every 30 minutes.

#### **CAR PARK**

Parking space is available next to the SECC and participants arriving by car are advised to use these facilities. Parking fees are not included in the registration fee.

#### **TAXIS**

There is a Glasgow taxis rank (Hackney) pick-up and drop-off point at the east entrance adjacent to the Clyde auditorium. There are taxi ranks throughout the city. Main pick-up points include Buchanan Bus Station, Queen Street and Central Stations and most large hotels. A one way trip from the city centre will cost approx. £5.00.

## ACKNOWLEDGEMENTS/SATELLITE SYMPOSIA

The organizers of the 5<sup>th</sup> World Congress on ADHD gratefully acknowledge the support of the following companies (as per May 2015):

#### PRINCIPLE SPONSOR

#### Shire



## SPONSORS

- ▶ Eye Brain
- ▶ Hayward Medical Communication
- ▶ MEDICE Arzneimittel Pütter & Co. KG
- ▶ neuroConn GmbH
- ▶ Qbtech Ltd.
- ▶ Sandoz Ltd.
- ▶ The TOVA Company
- ▶ Wisepress Ltd.

#### NON-COMMERCIAL SPONSOR

Glasgow City Council

## SATELLITE SYMPOSIA

Friday, 29 May 2015

SA-01	Industry	sponsored	symposiu
JA-U	III WUSU Y	3porisor eu	3 y i i i posiu

12:45 – 14:00 Lomond Auditorium

#### TIMES ARE CHANGING IN ADHD

### An audience-expert panel discussion forum

Times are changing across the ADHD landscape and, with the launch of new medications, so too are our ADHD treatment choices. An international panel of experts will discuss today's treatment options and share their own clinical practice experience on why, when and how switching treatments may improve outcomes for appropriate children, adolescents and adults with ADHD.

#### International Panel:

Moderator: Hilary Jones, UK

Tim Bilkey, Canada; Matthew Brams, USA; Ana Figueroa, Spain; Jürgen Fleischmann, Germany; Giovanni Giaroli, UK; Matt McConkey, UK; Joel Young, USA

A Shire organised and funded symposium.


SA-02	Industry sponsored symposium
12:45-13:45	Forth Room
SA-02-01	Introduction to symposium chairman Johannes Thome, Germany
SA-02-02	What are the clinical features of adult ADHD in the clinic? What do we know beyond DSM-5? Kobus van Rensburg, United Kingdom
SA-02-03	A focus on trajectory of response and maintenance of response of ADHD medications. Learnings for clinicians and patients Chris Bushe, United Kingdom
SA-02-04	Open debate and discussion. Implications for future guidelines Johannes Thome, Germany
	Supported by an unrestricted educational grant from Eli Lilly and Company.



## LIST OF EXHIBITORS AND MAP

Company	Booth No.
Principal Sponsor	
Shire	3/4
General Exhibitors	
ADHD Foundation	13
CADDRA	6
Eye Brain	5
Hayward	15
MEDICE Arzneimittel Pütter GmbH & Co. KG	2

Company	Booth No.
neuroCONN GmbH	7
Obtech Ltd.	8
Sandoz Ltd.	9
The TOVA Company	10
Wisepress Ltd.	1
World Federation of ADHD	14



## LIST OF CHAIRPERSONS AND PRESENTERS

A
Ackermann, S24
Adriani, W
Almeida, M
Arns, M
Asherson, P
Avancini, T
Azouz, H
В
Bae, JH
Bae. S. M
Banaschewski, T
Bangma, D. F
Barth, B
Bau, C
Becker, S
Bellgrove, M
Bhide, S
Biederman, J
Bihlar Muld, B
Bilke-Hentsch, O24
Blume, F
Boix, C
Bonnefois, G
Brahim, T
Bramham, J
Brandeis, D
Breda, V
Brown, T
Bruyckere, K. de
Budd, C
Buitelaar, J
Bushe, C
Bushe, C
Bushe, C
Bushe, C.       27         C       27         Cablova, L.       41         Caci, H.       28
Bushe, C
Bushe, C.       27         C       27         Cablova, L.       41         Caci, H.       28         Carr-Fanning, K.       28
Bushe, C       27         C       28         Caci, H       28         Carr-Fanning, K       28         Castellanos, F. X       15, 31, 43
Bushe, C.       27         C       28         Caci, H.       28         Carr-Fanning, K.       28         Castellanos, F. X.       15, 31, 43         Chang, J. PC.       28
Bushe, C.       27         C       28         Caci, H.       28         Carr-Fanning, K.       28         Castellanos, F. X.       15, 31, 43         Chang, J. PC.       28         Chen, K.       28
Bushe, C
Bushe, C
Bushe, C
Bushe, C.       27         C       28         Caci, H.       28         Carr-Fanning, K.       28         Castellanos, F. X.       15, 31, 43         Chang, J. PC.       28         Chen, K.       28         Chirita, A. L.       36         Coghill, D.       19, 44         Colomer, C.       41         Conzelmann, A.       23
Bushe, C.       27         C       28         Carr-Fanning, K.       28         Castellanos, F. X.       15, 31, 43         Chang, J. PC.       28         Chen, K.       28         Chirita, A. L.       36         Coghill, D.       19, 44         Colomer, C.       41         Conzelmann, A.       23         Cortese, S.       15, 36, 43
Bushe, C.       27         C       28         Carr-Fanning, K.       28         Castellanos, F. X.       15, 31, 43         Chang, J. PC.       28         Chen, K.       28         Chirita, A. L.       36         Coghill, D.       19, 44         Colomer, C.       41         Conzelmann, A.       23         Cortese, S.       15, 36, 43
Bushe, C.       27         C       28         Carr, Fanning, K.       28         Castellanos, F. X.       15, 31, 43         Chang, J. PC.       28         Chen, K.       28         Chirita, A. L.       36         Coghill, D.       19, 44         Colomer, C.       41         Conzelmann, A.       23         Cortese, S.       15, 36, 43         D         Dabkowski, M.       28
Bushe, C.       27         C       41         Caci, H.       28         Carr-Fanning, K.       28         Castellanos, F. X.       15, 31, 43         Chang, J. PC.       28         Chen, K.       28         Chirita, A. L.       36         Coghill, D.       19, 44         Colomer, C.       41         Conzelmann, A.       23         Cortese, S.       15, 36, 43         D         Dabkowski, M.       28         Daley, D.       28
Bushe, C.       27         C       28         Carr, Fanning, K.       28         Castellanos, F. X.       15, 31, 43         Chang, J. PC.       28         Chen, K.       28         Chirita, A. L.       36         Coghill, D.       19, 44         Colomer, C.       41         Conzelmann, A.       23         Cortese, S.       15, 36, 43         D         Dabkowski, M.       28
Bushe, C.       27         C
Bushe, C       27         C       28         Carr, H       28         Carr-Fanning, K       28         Castellanos, F. X       15, 31, 43         Chang, J. PC       28         Chen, K       28         Chirita, A. L       36         Coghill, D       19, 44         Colomer, C       41         Conzelmann, A       23         Cortese, S       15, 36, 43         D         Dabkowski, M       28         Daley, D       28         Dalsgaard, S       16, 18         Demir, N       20
Bushe, C       27         C       28         Carr, H       28         Carrefanning, K       28         Castellanos, F. X       15, 31, 43         Chang, J. PC       28         Chen, K       28         Chirita, A. L       36         Coghill, D       19, 44         Colomer, C       41         Conzelmann, A       23         Cortese, S       15, 36, 43         D         Dabkowski, M       28         Daley, D       28         Dalsgaard, S       16, 18         Demir, N       20         Deppermann, S       22
Bushe, C       27         C       28         Carr, H       28         Carr-Fanning, K       28         Castellanos, F. X       15, 31, 43         Chang, J. PC       28         Chen, K       28         Chirita, A. L       36         Coghill, D       19, 44         Colomer, C       41         Conzelmann, A       23         Cortese, S       15, 36, 43         D         Dabkowski, M       28         Daley, D       28         Dalsgaard, S       16, 18         Demir, N       20         Deppermann, S       22         Diaz-Orueta, U       37, 42
Bushe, C       27         C         Cablova, L       41         Caci, H       28         Carr-Fanning, K       28         Castellanos, F. X       15, 31, 43         Chang, J. PC       28         Chen, K       28         Chirita, A. L       36         Coghill, D       19, 44         Colomer, C       41         Conzelmann, A       23         Cortese, S       15, 36, 43         D         Dabkowski, M       28         Daley, D       28         Dalsgaard, S       16, 18         Demir, N       20         Deppermann, S       22         Diaz-Orueta, U       37, 42         Diers, S       28
Bushe, C       27         C       28         Carr, H       28         Carr, Fanning, K       28         Castellanos, F. X       15, 31, 43         Chang, J. PC       28         Chen, K       28         Chirita, A. L       36         Coghill, D       19, 44         Colomer, C       41         Conzelmann, A       23         Cortese, S       15, 36, 43         D         Dabkowski, M       28         Daley, D       28         Dalsgaard, S       16, 18         Demir, N       20         Deppermann, S       22         Diaz-Orueta, U       37, 42         Diers, S       28         Digiuni, M       24
Bushe, C       27         C       28         Carr, H       28         Carr, Fanning, K       28         Castellanos, F. X       15, 31, 43         Chang, J. PC       28         Chen, K       28         Chirita, A. L       36         Coghill, D       19, 44         Colomer, C       41         Conzelmann, A       23         Cortese, S       15, 36, 43         D         Dabkowski, M       28         Daley, D       28         Dalsgaard, S       16, 18         Demir, N       20         Deppermann, S       22         Diaz-Orueta, U       37, 42         Diers, S       28         Digiuni, M       24         Divino Lobo, G. A       20
Bushe, C       27         C         Cablova, L       41         Caci, H       28         Carr-Fanning, K       28         Castellanos, F. X       15, 31, 43         Chang, J. PC       28         Chen, K       28         Chirita, A. L       36         Coghill, D       19, 44         Colomer, C       41         Conzelmann, A       23         Cortese, S       15, 36, 43         D         D         Dabkowski, M       28         Dalsgaard, S       15, 36, 43         D         Dabkowski, M       28         Dalsgaard, S       16, 18         Demir, N       20         Deppermann, S       22         Diaz-Orueta, U       37, 42         Diers, S       28         Digiuni, M       24         Divino Lobo, G. A       20         Döpfner, M       31
Bushe, C       27         C       28         Carr, H       28         Carr, Fanning, K       28         Castellanos, F. X       15, 31, 43         Chang, J. PC       28         Chen, K       28         Chirita, A. L       36         Coghill, D       19, 44         Colomer, C       41         Conzelmann, A       23         Cortese, S       15, 36, 43         D         Dabkowski, M       28         Daley, D       28         Dalsgaard, S       16, 18         Demir, N       20         Deppermann, S       22         Diaz-Orueta, U       37, 42         Diers, S       28         Digiuni, M       24         Divino Lobo, G. A       20         Döpfner, M       31         Dovis, S       24
Bushe, C       27         C         Cablova, L       41         Caci, H       28         Carr-Fanning, K       28         Castellanos, F. X       15, 31, 43         Chang, J. PC       28         Chen, K       28         Chirita, A. L       36         Coghill, D       19, 44         Colomer, C       41         Conzelmann, A       23         Cortese, S       15, 36, 43         D         Dabkowski, M       28         Dalsgaard, S       16, 18         Demir, N       20         Deppermann, S       22         Diaz-Orueta, U       37, 42         Diers, S       28         Digiuni, M       24         Divino Lobo, G. A       20         Döpfner, M       31         Dovis, S       24         Drepper, C       30

E	
	28
Ehlis, A. C.	22
Einarsdottir, S.	24
F	
<b>r</b> Fair, D	1.0
·	
Fallgatter, A	
Faraone, S	
Fernández Díaz, A	
Fibert, P	
Fischer, R.	
Fischer, S.	
Franke, B	
Fuermaier, A. B. M	
Furuhashi, Y.	
Tururiasiii, 1	
G	
Gaastra, G.	42
Gaddour, N.	
Gallego Villalta, S.	21
Galvao-Carmona, A.	
Ganjiwale, D.	
Gao, H	
Gao, Q	
Gawrilow, C	2, 45
Geissler, J	
Gerlach, M.	
Ginsberg, Y.	15
Giupponi, G.	20
Godefroid, E.	
Gonzales, B.	42
Gonzalez, R.	41
Göttgens-Jansen, W.	
Greven, C.	
Groen, Y.	
Gross-Lesch, S.	36
Günther, T.	
Gurkan, C. K.	42
Н	
Haack, L	25
Haavik, J.	
Halldórsson, T. I.	
Halperin, J	9, 44
Hamada, M.	
Hegerl, U	
Hellwig, L	
Henríquez-Henríquez, M.	20
Herguner, S.	39
Hire, A	20
Hirvikoski, T.	38
Holmes, J	29
Hong, J	29
Hong, M	
Hoogman, M	25
Huang, F	
Tidalig, 1	17
Hudak, J.	17 39 37
Hudak, J. Human, W.	17 39 37
Hudak, J.	17 39 37
Hudak, J. Human, W.	17 39 37 35



## LIST OF CHAIRPERSONS AND PRESENTERS

1		Maire, J	
Ibrahim, O	20	Malomo, O	29
Igarashi, M	29	Marín-Méndez, J. J	21
ljaz-Ul-Haq, R	41	Martinez-Raga, J	42
Imeraj, L		Martsenkovsky, I	
Instanes, J.		Martsenkovskyi, D	33
Instebø, K.		Massé, L	25
		Matthys, F	
Ito, H.		Mattos, P.	
Ivanov, I.			
Izquierdo Herrero, E	21	Mcconkey, M	
		McGuffin, P	
J		Mckee, T	
Jacir, N	21	Medrano, E	23
Jaimes-Albornoz, W.		Melegari, M. G	22
Jain, R		Merkt, J	34
James, S.		Merlo, G	25
Javier, I.		Merzon, E	
-		Michelini, G.	
Jensen, C. M.		Miguel, C. S	
Jepsen, J. R. M.		Morita, T	
Jin, J			
Jones, R		Müller, U	
Joseph, A	26, 27	Mundo Cid, P	
Jurma, A. M	28	Murtani, B. J	21
.,		N	
K		Nari, K	7.1
Karam, R.		Naruse, H.	
Kashirina, S			
Kautzky, A	37	Neuhaus, C	
Kavanagh, G	34	Newcorn, J	
Kerridge, A	25	Niederhofer, H	
Kim, BN	20, 26	Nielsen, N. P	27
Kim, H	·	Nigg, J. T	18
Kim, J. W		Norman, L	38
Kiselev, S.			
Kittel-Schneider, S.		0	
· · · · · · · · · · · · · · · · · · ·		Oerlemans, A	10
Klassen, L.		The state of the s	
Klein, M		Okajima, Y	
Klein, R. G.	18, 20, 30, 31	Oldehinkel, M	
Koelle, M	27	Onandia, I	
Kohls, G	18, 25	Oros, M	
Kollins, S. H	32	Ozten, E	36
Kooij, S			
Kuntsi, J.		P	
Kutscheidt, K.		Palacios-Cruz, L	22.26
•		Palma, S. M.	
Kylyc, B. G		•	
_		Paolini, J	
L		Park, K. J	
Lambregts-Rommelse, N	19	Park, S	
Lange, K. W	15, 19, 40	Parlatini, V	15
La Pena, J. B. de	29	Perera, S	36
Lee, X		Peres, C	38
Lesch, KP.		Perez Algorta, G	
Le Sommer, J.	•	Perroud, N	
		Pfiffner, L.	
Leventhal, N		Philipp-Wiegmann, F	
Liu, C. A			
Liu, L		Philipsen, A	
Li-Yu, S.	25	Polanczyk, G	
Llopart, L	41	Pollak, Y	
Lopez Seco, F	28, 33	Posener, E	26
Lourenço, N.		Poulton, A	33
Low, AM.		Protti, E	
LOVY, / 1. IVI.		Pruim, R.	
M			
Mackenzie, G	28	Q	
Mahone, M.		Qian, Q	36
Maia, C.		Quinn, D.	
ividia, C	47	Z/ 2	20, 73, 47

## LIST OF CHAIRPERSONS AND PRESENTERS

R		T
Radua, J	37	Takamura, T
Ramos-Quiroga, J. A	16, 30, 46	Takon, I
Ramsay, R		Taskiran, S
Reid, A	23	Taylor, E
Reimherr, F		Teixeira Leffa, D
Renner, T	18	Thome, J
Retz, W		Thompson, M
Riederer, P.		Tiesler, C.
Robaey, P.		Tokumasu, T
Rohde, L. A.		Toma, M
Romanos, M.		Topal, Z
Roselló, R.		Torgersen, T.
Rosetti, M.		Toye, M
Rösler, M.		Tsujii, M
Rossi, A.		Tucha, L
Roy, D.		Tucha, O
Rubia, K.		таспа, О
		U
Russell, A.		Uemiya, A
Ryckaert, C.		Ulloa, E.
Rydell, M.		Upadhyaya, H
Rzenca, K.	38	opaariyaya, 11.
_		V
\$		Vallejo, M
Sabery, H.		van Cauwenberge, V
Saga, N		van de Glind, G
Salomone, S		van den Bergh, B.
Salum, G	17	van der Oord, S.
Sanli, I.	35	van Emmerik-van Oortmerssen, K.
Santos, V	29	van Ewijk, H
Sarver, D. E	16, 37	Vanicek, T.
Sayal, K	32	van Stralen, J.
Schiebler, S	40	Viana, C
Schilpzand, E.		Vidal, R
Schmiedek, F.	30	Vincent, A.
Schote-Frese, A	17	Viola, L
Schulz-Zhecheva, Y		Vogel, S
Sciberras, E	19, 40	Volkert, J
Seassau, M		voilert, J.
Sedova, E	38	W
Seleem, M.	33	Wachnianin, H
Sevilla, J.	36	Walitza, S
Shimabukuro, S.	38	Warnke, A
Shin, MS	42	Weiss, M.
Shokoohi-Yekta, M	30	Werling, A. M
Silk, T. J	15	Wibowo, J. A.
Silva, D	15, 28	Wilens, T. E.
Silva, F	40	Wolters, E.
Simonoff, E.	19	Wong, I.
Skounti, M.		Wozniak-Prus, M.
Snitselaar, M.		Wu, Z
Solanto, M.		Wynchank, D.
Son, J. H		vvyrichank, D
Son, JW		Υ
Sonuga-Barke, E. J. S.		Yang, L
Sorensen, L.		Yaremko, J. F.
Steiner, N.		Yoo, H
Steinhausen, HC.		Youdim, M
Stein, M.		Young, S.
Stralen, J. van		Yu, X
Strauß, M.		ιω, Λ
Sugmioto, N.		Z
Suh, C.		Zaman, R
Sun, L.		Zendarski, N
Surman, C. B.		Zheng, Y.
Swanson, J.		Zuddas, A.
Sznindel I		

	29
Takon, I	
Taskiran, S.	34
Taylor, E35, 4	14
Teixeira Leffa, D.	29
Thome, J	14
Thompson, M.	
Tiesler, C	
Tokumasu, T.	
Toma, M.	
Topal, Z.	
Torgersen, T.	
Toye, M.	
Tsujii, M	
Tucha, L	
Tucha, O	40
U	
Uemiya, A.	35
Ulloa, E.	
Upadhyaya, H	
Ораипуауа, п	_ /
V	
Vallejo, M.	39
van Cauwenberge, V	22
van de Glind, G	11
van den Bergh, B	32
van der Oord, S.	19
van Emmerik-van Oortmerssen, K	
van Ewijk, H1	
Vanicek, T	
van Stralen, J	
Viana, C.	
Vidal, R	38
Vincent, A.	
Vincent, A	
	15
Viola, L	15 33
Viola, L	15 33
Viola, L	15 33
Viola, L.       1         Vogel, S.       3         Volkert, J.       1         W	15 33 18
Viola, L.       1         Vogel, S.       3         Volkert, J.       1         W       Wachnianin, H.	15 33 18
Viola, L.       1         Vogel, S.       3         Volkert, J.       1         W       Wachnianin, H.       4         Walitza, S.       16, 18, 2	15 33 18 40 21
Viola, L.       1         Vogel, S.       3         Volkert, J.       1         W       M         Wachnianin, H.       4         Walitza, S.       16, 18, 2         Warnke, A.       18, 2	15 33 18 40 21 21
Viola, L.       1         Vogel, S.       3         Volkert, J.       1         W       Wachnianin, H.         Walitza, S.       16, 18, 2         Warnke, A.       18, 2         Weiss, M.       4	15 33 18 40 21 21
Viola, L.       1         Vogel, S.       3         Volkert, J.       1         W       1         Wachnianin, H.       4         Walitza, S.       16, 18, 2         Warnke, A.       18, 2         Weiss, M.       4         Werling, A. M.       3	15 33 18 40 21 21 43 35
Viola, L.       1         Vogel, S.       3         Volkert, J.       1         W       1         Wachnianin, H.       4         Walitza, S.       16, 18, 2         Warnke, A.       18, 2         Weiss, M.       4         Werling, A. M.       3         Wibowo, J. A.       3	15 33 18 40 21 43 35 33
Viola, L.       1         Vogel, S.       3         Volkert, J.       1         W       1         Wachnianin, H.       4         Walitza, S.       16, 18, 2         Warnke, A.       18, 2         Weiss, M.       4         Werling, A. M.       3	15 33 18 40 21 43 35 33
Viola, L.       1         Vogel, S.       3         Volkert, J.       1         W       1         Wachnianin, H.       4         Walitza, S.       16, 18, 2         Warnke, A.       18, 2         Weiss, M.       4         Werling, A. M.       3         Wibowo, J. A.       3	15 33 18 40 21 43 35 33 39
Viola, L.       1         Vogel, S.       3         Volkert, J.       1         W       1         Wachnianin, H.       4         Walitza, S.       16, 18, 2         Warnke, A.       18, 2         Weiss, M.       4         Werling, A. M.       5         Wilens, T. E.       3         Wolters, E.       3	15 33 18 40 21 21 43 35 33 39
Viola, L.       1         Vogel, S.       3         Volkert, J.       1         W       Wachnianin, H.       2         Walitza, S.       16, 18, 2         Warnke, A.       18, 2         Weiss, M.       2         Werling, A. M.       3         Wilens, T. E.       3         Wolters, E.       3         Wong, I.       4	15 33 18 40 21 43 35 33 39 32 41
Viola, L.       1         Vogel, S.       3         Volkert, J.       1         W       Wachnianin, H.       2         Walitza, S.       16, 18, 2         Warnke, A.       18, 2         Weiss, M.       2         Werling, A. M.       3         Wilens, T. E.       3         Wolters, E.       3         Wozniak-Prus, M.       4	15 33 18 40 21 43 35 33 39 31 41
Viola, L.       1         Vogel, S.       3         Volkert, J.       1         W       1         Wachnianin, H.       2         Walitza, S.       16, 18, 2         Warnke, A.       18, 2         Weiss, M.       2         Werling, A. M.       3         Wibowo, J. A.       3         Wilens, T. E.       3         Wolters, E.       3         Wozniak-Prus, M.       4         Wu, Z.       2	15 33 18 40 21 43 35 33 39 32 41 41 24
Viola, L.       1         Vogel, S.       3         Volkert, J.       1         W       Wachnianin, H.       2         Walitza, S.       16, 18, 2         Warnke, A.       18, 2         Weiss, M.       2         Werling, A. M.       3         Wilens, T. E.       3         Wolters, E.       3         Wozniak-Prus, M.       4	15 33 18 40 21 43 35 33 39 32 41 41 24
Viola, L.       1         Vogel, S.       3         Volkert, J.       1         W       1         Wachnianin, H.       2         Walitza, S.       16, 18, 2         Warnke, A.       18, 2         Werling, A. M.       3         Wibowo, J. A.       3         Wilens, T. E.       3         Wolters, E.       3         Wozniak-Prus, M.       4         Wu, Z.       2         Wynchank, D.       3	15 33 18 40 21 43 35 33 39 32 41 41 24
Viola, L.       1         Vogel, S.       3         Volkert, J.       1         W       1         Wachnianin, H.       2         Walitza, S.       16, 18, 2         Warnke, A.       18, 2         Werling, A. M.       3         Wibowo, J. A.       3         Wilens, T. E.       3         Wolters, E.       3         Wozniak-Prus, M.       4         Wu, Z.       2         Wynchank, D.       3	15 33 18 40 21 43 35 33 39 41 41 24 36
Viola, L.       1         Vogel, S.       3         Volkert, J.       1         W       1         Wachnianin, H.       2         Walitza, S.       16, 18, 2         Warnke, A.       18, 2         Werling, A. M.       3         Wibowo, J. A.       3         Wilens, T. E.       3         Wolters, E.       3         Wozniak-Prus, M.       4         Wu, Z.       2         Wynchank, D.       3         Y       Yang, L.	15 33 18 40 21 43 35 33 39 32 41 41 24 36
Viola, L.       1         Vogel, S.       3         Volkert, J.       1         W       1         Wachnianin, H.       2         Walitza, S.       16, 18, 2         Warnke, A.       18, 2         Werling, A. M.       3         Wibowo, J. A.       3         Wilens, T. E.       3         Wolters, E.       3         Wozniak-Prus, M.       4         Wu, Z.       2         Wynchank, D.       3         Y       Yang, L.         Yaremko, J. F.       2	15 33 18 40 21 43 35 33 39 32 41 41 24 36
Viola, L.       1         Vogel, S.       3         Volkert, J.       1         W       1         Wachnianin, H.       2         Walitza, S.       16, 18, 2         Warnke, A.       18, 2         Werling, A. M.       3         Wilens, T. E.       3         Wolters, E.       3         Wozniak-Prus, M.       2         Wu, Z.       2         Wynchank, D.       3         Y       Yang, L.       3         Yaremko, J. F.       4         Yoo, H.       4	15 33 18 40 21 43 35 33 39 32 41 41 24 36
Viola, L.       1         Vogel, S.       3         Volkert, J.       1         W       1         Wachnianin, H.       2         Walitza, S.       16, 18, 2         Warnke, A.       18, 2         Werling, A. M.       3         Wibowo, J. A.       3         Wilens, T. E.       3         Wolters, E.       3         Wozniak-Prus, M.       4         Wu, Z.       2         Wynchank, D.       3         Y       Yang, L.         Yaremko, J. F.       2	15 33 18 40 21 43 35 33 39 32 41 41 24 36
Viola, L.       1         Vogel, S.       3         Volkert, J.       1         W       1         Wachnianin, H.       2         Walitza, S.       16, 18, 2         Warnke, A.       18, 2         Werling, A. M.       3         Wilens, T. E.       3         Wolters, E.       3         Wozniak-Prus, M.       2         Wu, Z.       2         Wynchank, D.       3         Y       Yang, L.       3         Yaremko, J. F.       4         Yoo, H.       4	15 33 18 40 21 43 35 33 39 32 41 41 24 36 38 41 43 32
Viola, L.       1         Vogel, S.       3         Volkert, J.       1         W       1         Walitza, S.       16, 18, 2         Warnke, A.       18, 2         Werling, A. M.       3         Wilens, T. E.       3         Wolters, E.       3         Wozniak-Prus, M.       4         Wu, Z.       2         Wynchank, D.       3         Y       Yaremko, J. F.       4         Yoo, H.       4         Youdim, M.       3	15 33 18 40 21 43 35 33 39 32 41 41 24 36 38 41 43 32 15
Viola, L.       1         Vogel, S.       3         Volkert, J.       1         W       1         Walitza, S.       16, 18, 2         Warnke, A.       18, 2         Werling, A. M.       3         Wilens, T. E.       3         Wolters, E.       3         Wozniak-Prus, M.       4         Wu, Z.       2         Wynchank, D.       3         Yaremko, J. F.       4         Yoo, H.       4         Youdim, M.       3         Young, S.       1	15 33 18 40 21 43 35 33 39 32 41 41 24 36 38 41 43 32 15
Viola, L.       1         Vogel, S.       3         Volkert, J.       1         W       1         Walitza, S.       16, 18, 2         Warnke, A.       18, 2         Werling, A. M.       3         Wilens, T. E.       3         Wolters, E.       3         Wozniak-Prus, M.       4         Wu, Z.       2         Wynchank, D.       3         Yaremko, J. F.       4         Yoo, H.       4         Youdim, M.       3         Young, S.       1	15 33 18 40 21 43 35 33 39 32 41 41 24 36 38 41 43 32 15
Viola, L.       1         Vogel, S.       3         Volkert, J.       1         W       1         Wachnianin, H.       2         Walitza, S.       16, 18, 2         Warnke, A.       18, 2         Werling, A. M.       3         Wilens, T. E.       3         Wolters, E.       3         Wozniak-Prus, M.       4         Wu, Z.       2         Wynchank, D.       3         Yaremko, J. F.       4         Yoo, H.       4         Youdim, M.       3         Young, S.       1         Yu, X.       2	15 33 18 40 21 43 35 33 39 32 41 41 43 36 38 41 43 43 43 43 44 43 43 44 44 43 44 44 44
Viola, L	15 33 18 40 21 43 33 33 33 41 41 43 32 44 44
Viola, L.       1         Vogel, S.       3         Volkert, J.       1         W       1         Wachnianin, H.       2         Walitza, S.       16, 18, 2         Warnke, A.       18, 2         Werling, A. M.       3         Wilens, T. E.       3         Wolters, E.       3         Wozniak-Prus, M.       4         Wu, Z.       2         Wynchank, D.       3         Yaremko, J. F.       4         Yoo, H.       4         Youdim, M.       3         Young, S.       1         Yu, X.       2         Zaman, R.       2         Zendarski, N.       2	15 33 18 40 21 43 35 33 33 33 41 41 43 43 44 41
Viola, L.       1         Vogel, S.       3         Volkert, J.       1         W       1         Wachnianin, H.       2         Walitza, S.       16, 18, 2         Warnke, A.       18, 2         Werling, A. M.       3         Wibowo, J. A.       3         Wilens, T. E.       3         Woong, I.       4         Wozniak-Prus, M.       4         Wu, Z.       2         Wynchank, D.       3         Yang, L.       3         Yaremko, J. F.       4         Youdim, M.       3         Young, S.       1         Yu, X.       2         Zaman, R.       4         Zendarski, N.       4         Zheng, Y.       15, 4	15 318 40 21 43 35 33 33 33 41 41 43 43 44 41 41
Viola, L.       1         Vogel, S.       3         Volkert, J.       1         W       1         Wachnianin, H.       2         Walitza, S.       16, 18, 2         Warnke, A.       18, 2         Werling, A. M.       3         Wilens, T. E.       3         Wolters, E.       3         Wozniak-Prus, M.       4         Wu, Z.       2         Wynchank, D.       3         Yaremko, J. F.       4         Yoo, H.       4         Youdim, M.       3         Young, S.       1         Yu, X.       2         Zaman, R.       2         Zendarski, N.       2	15 318 40 21 43 35 33 33 33 41 41 43 43 44 41 41



## We organize your success

CPO HANSER SERVICE is specialist in the field of Conference, Event, Destination and Association Management organizing events of any size throughout Germany and also abroad for more than 30 years.



CONFERENCE - EVENT - DESTINATION - ASSOCIATION MANAGEMENT - IT SOLUTIONS

## We offer you:

- the best congress organization
- state-of-the-art online solutions
- electronic abstract handling
- CME accreditation handling
- effective congress technology
- sponsoring and exhibition acquisition and management
- finance management
- professional tax solutions
- creative event programs
- websites and apps
- graphic design
- association management

#### **BERLIN**

Paulsborner Straße 44 14193 Berlin

fon +49-30-300 669 0 fax +49-30-305 73 91 Email: berlin@cpo-hanser.de

### HAMBURG

Zum Ehrenhain 34 22885 Barsbüttel

fon +49-40-670 882 0 fax +49-40-670 32 83 Email: hamburg@cpo-hanser.de

#### **GLOBIT HAMBURG**

Am Akku 7 22885 Barsbüttel

fon +49-40-670 882 0 fax +49-40-670 32 83 Email: info@globit.com

## www.cpo-hanser.de













www.adhd-congress.org

## CONGRESS AND EXHIBITION OFFICE

## CPOMANSER® SERVICE

## **Hamburg Office**

CPO HANSER SERVICE Zum Ehrenhain 34

22885 Barsbüttel, Germany Phone:+49-40-670 88 20

Fax: +49-40-670 32 83 Email: adhd2015@cpo-hanser.de

www.adhd-congress.org